Covered recipient · General Payments record
BRUCE RANKIN
Allopathic & Osteopathic Physicians Family Medicine
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$1,612.22
12 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Travel and Lodging | $1,013.69 | 4 |
| Food and Beverage | $598.53 | 8 |
By paying entity
PY2024 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ModernaTX, Inc. | $1,394.72 | 10 |
| Amgen Inc. | $120.83 | 1 |
| Lilly USA, LLC | $96.67 | 1 |
Page 1 of 1; records 1–12 of 12 matching records. This page contains 12 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
BRUCE RANKIN
NPI 1922027853 · CMS profile ID 132925
Allopathic & Osteopathic Physicians / Family Medicine
DELAND, FL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–12 of 12 matching records. This page contains 12 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1922027853?year=2024&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- BRUCE RANKIN, NPI 1922027853, CMS profile ID 132925. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–12 of 12 matching records. This page contains 12 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1922027853?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). BRUCE RANKIN, NPI 1922027853, CMS profile ID 132925. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–12 of 12 matching records. This page contains 12 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1922027853?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- BRUCE RANKIN, NPI 1922027853, CMS profile ID 132925, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–12 of 12 matching records. This page contains 12 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1922027853?year=2024&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
12 matching records · $1,612.22 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–12 of 12.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| ModernaTX, Inc. | $75.03 | 09/14/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1152558244 | CMS |
| ModernaTX, Inc. | $451.96 | 09/14/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1152558246 | CMS |
| ModernaTX, Inc. | $240.00 | 09/14/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1152558248 | CMS |
| ModernaTX, Inc. | $56.20 | 09/14/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1152558250 | CMS |
| ModernaTX, Inc. | $265.53 | 09/14/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1152558252 | CMS |
| ModernaTX, Inc. | $30.00 | 09/14/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1152558254 | CMS |
| ModernaTX, Inc. | $81.00 | 09/14/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1152558256 | CMS |
| ModernaTX, Inc. | $30.00 | 09/14/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1152558258 | CMS |
| ModernaTX, Inc. | $45.00 | 09/14/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1152558260 | CMS |
| ModernaTX, Inc. | $120.00 | 09/14/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1152558262 | CMS |
| Amgen Inc. | $120.83 | 08/29/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1111684396 | CMS |
| Lilly USA, LLC | $96.67 | 05/30/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1136080574 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $1,755.45 | 1 |
| PY2025 | Principal investigator | $4,230,288.19 | 209 |
| PY2024 | Recipient | $1,330.16 | 13 |
| PY2024 | Principal investigator | $3,187,354.20 | 327 |
| PY2023 | Recipient | $893.27 | 4 |
| PY2023 | Principal investigator | $6,323,793.75 | 2,767 |
| PY2022 | Recipient | $462.00 | 2 |
| PY2022 | Principal investigator | $6,941,300.42 | 589 |
| PY2021 | Recipient | $15.00 | 1 |
| PY2021 | Principal investigator | $10,036,876.19 | 348 |
| PY2020 | Recipient | $10,602.17 | 4 |
| PY2020 | Principal investigator | $3,545,507.10 | 644 |
| PY2019 | Principal investigator | $2,410,610.06 | 875 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2023
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
2,771 records in PY2023
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $398.57 | 12/31/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma | No dispute reported | 06/30/2026 | 991132829 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $14,566.32 | 12/31/2023 | Non-covered Recipient Entity Accel Research Sites-DeLand Clinical Research Unit | A Phase 3, Multicenter, Open-Label Study to Evaluate the Safety and Immunogenicity of 2-dose Regimens of 9vHPV and mRNA-1273 SARS-CoV-2 Vaccines Where the First Dose of Each Vaccine Are Given Concomitantly in Boys and Girls 9 to 11 Years of Age | No dispute reported | 06/30/2026 | 1042488571 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $234.24 | 12/31/2023 | Non-covered Recipient Entity Accel Research Sites-DeLand Clinical Research Unit | A Phase 3, Multicenter, Open-Label Study to Evaluate the Safety and Immunogenicity of 2-dose Regimens of 9vHPV and mRNA-1273 SARS-CoV-2 Vaccines Where the First Dose of Each Vaccine Are Given Concomitantly in Boys and Girls 9 to 11 Years of Age | No dispute reported | 06/30/2026 | 1042488573 |
| Principal investigator 1 | ModernaTX, Inc. | $3,431.40 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041444901 |
| Principal investigator 1 | ModernaTX, Inc. | $1,652.00 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041444914 |
| Principal investigator 1 | ModernaTX, Inc. | $2,510.20 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041444925 |
| Principal investigator 1 | ModernaTX, Inc. | $1,334.20 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041444937 |
| Principal investigator 1 | ModernaTX, Inc. | $2,336.60 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041444947 |
| Principal investigator 1 | ModernaTX, Inc. | $1,421.00 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041444959 |
| Principal investigator 1 | ModernaTX, Inc. | $1,652.00 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041445175 |
| Principal investigator 1 | ModernaTX, Inc. | $2,510.20 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041445187 |
| Principal investigator 1 | ModernaTX, Inc. | $2,510.20 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041445201 |
| Principal investigator 1 | ModernaTX, Inc. | $2,510.20 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041445213 |
| Principal investigator 1 | ModernaTX, Inc. | $2,510.20 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041445227 |
| Principal investigator 1 | ModernaTX, Inc. | $1,652.00 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041445239 |
| Principal investigator 1 | ModernaTX, Inc. | $3,431.40 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041445251 |
| Principal investigator 1 | ModernaTX, Inc. | $1,652.00 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041445265 |
| Principal investigator 1 | ModernaTX, Inc. | $2,510.20 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041445279 |
| Principal investigator 1 | ModernaTX, Inc. | $1,334.20 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041445293 |
| Principal investigator 1 | ModernaTX, Inc. | $2,510.20 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041445303 |
| Principal investigator 1 | ModernaTX, Inc. | $2,336.60 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041445313 |
| Principal investigator 1 | ModernaTX, Inc. | $1,652.00 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041445323 |
| Principal investigator 1 | ModernaTX, Inc. | $2,510.20 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041445338 |
| Principal investigator 1 | ModernaTX, Inc. | $1,652.00 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041445351 |
| Principal investigator 1 | ModernaTX, Inc. | $2,336.60 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041445365 |
| Principal investigator 1 | ModernaTX, Inc. | $1,652.00 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041445375 |
| Principal investigator 1 | ModernaTX, Inc. | $2,510.20 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041445385 |
| Principal investigator 1 | ModernaTX, Inc. | $1,334.20 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041445399 |
| Principal investigator 1 | ModernaTX, Inc. | $3,431.40 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041445411 |
| Principal investigator 1 | ModernaTX, Inc. | $1,652.00 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041445425 |
| Principal investigator 1 | ModernaTX, Inc. | $1,652.00 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041445437 |
| Principal investigator 1 | ModernaTX, Inc. | $2,336.60 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041445453 |
| Principal investigator 1 | ModernaTX, Inc. | $1,652.00 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041445467 |
| Principal investigator 1 | ModernaTX, Inc. | $2,510.20 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041445483 |
| Principal investigator 1 | ModernaTX, Inc. | $1,334.20 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041445499 |
| Principal investigator 1 | ModernaTX, Inc. | $3,431.40 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041445513 |
| Principal investigator 1 | ModernaTX, Inc. | $3,431.40 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041445527 |
| Principal investigator 1 | ModernaTX, Inc. | $1,652.00 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041445545 |
| Principal investigator 1 | ModernaTX, Inc. | $1,334.20 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041445559 |
| Principal investigator 1 | ModernaTX, Inc. | $3,431.40 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041445575 |
| Principal investigator 1 | ModernaTX, Inc. | $2,510.20 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041445591 |
| Principal investigator 1 | ModernaTX, Inc. | $3,431.40 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041445607 |
| Principal investigator 1 | ModernaTX, Inc. | $1,652.00 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041445623 |
| Principal investigator 1 | ModernaTX, Inc. | $1,652.00 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041445639 |
| Principal investigator 1 | ModernaTX, Inc. | $3,431.40 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041445653 |
| Principal investigator 1 | ModernaTX, Inc. | $1,421.00 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041445671 |
| Principal investigator 1 | ModernaTX, Inc. | $2,510.20 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041445685 |
| Principal investigator 1 | ModernaTX, Inc. | $1,652.00 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041445703 |
| Principal investigator 1 | ModernaTX, Inc. | $2,510.20 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041445719 |
| Principal investigator 1 | ModernaTX, Inc. | $2,510.20 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041445735 |
| Principal investigator 1 | ModernaTX, Inc. | $3,431.40 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041445753 |
| Principal investigator 1 | ModernaTX, Inc. | $3,431.40 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041445817 |
| Principal investigator 1 | ModernaTX, Inc. | $2,510.20 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041445831 |
| Principal investigator 1 | ModernaTX, Inc. | $2,510.20 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041445847 |
| Principal investigator 1 | ModernaTX, Inc. | $1,334.20 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041445861 |
| Principal investigator 1 | ModernaTX, Inc. | $1,334.20 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041445877 |
| Principal investigator 1 | ModernaTX, Inc. | $3,431.40 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041445893 |
| Principal investigator 1 | ModernaTX, Inc. | $1,334.20 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041445907 |
| Principal investigator 1 | ModernaTX, Inc. | $3,431.40 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041445923 |
| Principal investigator 1 | ModernaTX, Inc. | $2,510.20 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041445937 |
| Principal investigator 1 | ModernaTX, Inc. | $3,431.40 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041445953 |
| Principal investigator 1 | ModernaTX, Inc. | $1,421.00 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041445969 |
| Principal investigator 1 | ModernaTX, Inc. | $3,431.40 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041445997 |
| Principal investigator 1 | ModernaTX, Inc. | $1,652.00 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041446335 |
| Principal investigator 1 | ModernaTX, Inc. | $1,421.00 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041446351 |
| Principal investigator 1 | ModernaTX, Inc. | $1,334.20 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041446367 |
| Principal investigator 1 | ModernaTX, Inc. | $2,510.20 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041446383 |
| Principal investigator 1 | ModernaTX, Inc. | $1,334.20 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041446399 |
| Principal investigator 1 | ModernaTX, Inc. | $1,652.00 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041446415 |
| Principal investigator 1 | ModernaTX, Inc. | $1,334.20 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041446431 |
| Principal investigator 1 | ModernaTX, Inc. | $1,334.20 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041446449 |
| Principal investigator 1 | ModernaTX, Inc. | $1,652.00 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041446465 |
| Principal investigator 1 | ModernaTX, Inc. | $1,421.00 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041446481 |
| Principal investigator 1 | ModernaTX, Inc. | $1,421.00 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041446497 |
| Principal investigator 1 | ModernaTX, Inc. | $1,334.20 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041446513 |
| Principal investigator 1 | ModernaTX, Inc. | $2,510.20 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041446527 |
| Principal investigator 1 | ModernaTX, Inc. | $1,652.00 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041446541 |
| Principal investigator 1 | ModernaTX, Inc. | $1,334.20 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041446557 |
| Principal investigator 1 | ModernaTX, Inc. | $2,510.20 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041446573 |
| Principal investigator 1 | ModernaTX, Inc. | $1,652.00 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041446591 |
| Principal investigator 1 | ModernaTX, Inc. | $1,334.20 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041446605 |
| Principal investigator 1 | ModernaTX, Inc. | $3,431.40 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041446619 |
| Principal investigator 1 | ModernaTX, Inc. | $2,336.60 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041446639 |
| Principal investigator 1 | ModernaTX, Inc. | $1,652.00 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041446657 |
| Principal investigator 1 | ModernaTX, Inc. | $3,431.40 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041446671 |
| Principal investigator 1 | ModernaTX, Inc. | $3,431.40 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041446683 |
| Principal investigator 1 | ModernaTX, Inc. | $2,510.20 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041446701 |
| Principal investigator 1 | ModernaTX, Inc. | $1,652.00 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041446719 |
| Principal investigator 1 | ModernaTX, Inc. | $3,431.40 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041446735 |
| Principal investigator 1 | ModernaTX, Inc. | $2,510.20 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041446751 |
| Principal investigator 1 | ModernaTX, Inc. | $2,336.60 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041446765 |
| Principal investigator 1 | ModernaTX, Inc. | $3,431.40 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041446779 |
| Principal investigator 1 | ModernaTX, Inc. | $1,334.20 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041446795 |
| Principal investigator 1 | ModernaTX, Inc. | $3,431.40 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041446809 |
| Principal investigator 1 | ModernaTX, Inc. | $1,421.00 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041446825 |
| Principal investigator 1 | ModernaTX, Inc. | $3,431.40 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041446841 |
| Principal investigator 1 | ModernaTX, Inc. | $2,510.20 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041446859 |
| Principal investigator 1 | ModernaTX, Inc. | $1,421.00 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041446877 |
| Principal investigator 1 | ModernaTX, Inc. | $1,334.20 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041446893 |
| Principal investigator 1 | ModernaTX, Inc. | $2,510.20 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041446909 |
| Principal investigator 1 | ModernaTX, Inc. | $1,652.00 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041446925 |
| Principal investigator 1 | ModernaTX, Inc. | $2,510.20 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041446939 |
| Principal investigator 1 | ModernaTX, Inc. | $3,431.40 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041446953 |
| Principal investigator 1 | ModernaTX, Inc. | $1,421.00 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041446969 |
| Principal investigator 1 | ModernaTX, Inc. | $2,336.60 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041446987 |
| Principal investigator 1 | ModernaTX, Inc. | $1,334.20 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041447003 |
| Principal investigator 1 | ModernaTX, Inc. | $1,652.00 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041447019 |
| Principal investigator 1 | ModernaTX, Inc. | $3,431.40 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041447033 |
| Principal investigator 1 | ModernaTX, Inc. | $2,336.60 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041447049 |
| Principal investigator 1 | ModernaTX, Inc. | $1,334.20 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041447063 |
| Principal investigator 1 | ModernaTX, Inc. | $3,431.40 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041447080 |
| Principal investigator 1 | ModernaTX, Inc. | $1,652.00 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041447095 |
| Principal investigator 1 | ModernaTX, Inc. | $1,652.00 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041447111 |
| Principal investigator 1 | ModernaTX, Inc. | $1,334.20 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041447127 |
| Principal investigator 1 | ModernaTX, Inc. | $1,334.20 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041447145 |
| Principal investigator 1 | ModernaTX, Inc. | $1,334.20 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041447161 |
| Principal investigator 1 | ModernaTX, Inc. | $1,652.00 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041447175 |
| Principal investigator 1 | ModernaTX, Inc. | $2,510.20 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041447189 |
| Principal investigator 1 | ModernaTX, Inc. | $1,334.20 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041447205 |
| Principal investigator 1 | ModernaTX, Inc. | $1,652.00 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041447221 |
| Principal investigator 1 | ModernaTX, Inc. | $1,334.20 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041447235 |
| Principal investigator 1 | ModernaTX, Inc. | $1,652.00 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041447251 |
| Principal investigator 1 | ModernaTX, Inc. | $3,431.40 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041447267 |
| Principal investigator 1 | ModernaTX, Inc. | $1,652.00 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041447283 |
| Principal investigator 1 | ModernaTX, Inc. | $2,510.20 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041447299 |
| Principal investigator 1 | ModernaTX, Inc. | $1,652.00 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041447315 |
| Principal investigator 1 | ModernaTX, Inc. | $2,510.20 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041447331 |
| Principal investigator 1 | ModernaTX, Inc. | $1,334.20 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041447349 |
| Principal investigator 1 | ModernaTX, Inc. | $3,431.40 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041447365 |
| Principal investigator 1 | ModernaTX, Inc. | $1,652.00 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041447381 |
| Principal investigator 1 | ModernaTX, Inc. | $2,510.20 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041447399 |
| Principal investigator 1 | ModernaTX, Inc. | $3,431.40 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041447415 |
| Principal investigator 1 | ModernaTX, Inc. | $1,334.20 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041447429 |
| Principal investigator 1 | ModernaTX, Inc. | $1,652.00 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041447445 |
| Principal investigator 1 | ModernaTX, Inc. | $1,334.20 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041447461 |
| Principal investigator 1 | ModernaTX, Inc. | $3,431.40 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041447477 |
| Principal investigator 1 | ModernaTX, Inc. | $3,431.40 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041447491 |
| Principal investigator 1 | ModernaTX, Inc. | $1,652.00 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041447508 |
| Principal investigator 1 | ModernaTX, Inc. | $1,652.00 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041447521 |
| Principal investigator 1 | ModernaTX, Inc. | $1,652.00 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041447538 |
| Principal investigator 1 | ModernaTX, Inc. | $1,652.00 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041447559 |
| Principal investigator 1 | ModernaTX, Inc. | $3,431.40 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041447573 |
| Principal investigator 1 | ModernaTX, Inc. | $3,431.40 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041447589 |
| Principal investigator 1 | ModernaTX, Inc. | $2,510.20 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041447605 |
| Principal investigator 1 | ModernaTX, Inc. | $2,336.60 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041447621 |
| Principal investigator 1 | ModernaTX, Inc. | $2,336.60 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041447635 |
| Principal investigator 1 | ModernaTX, Inc. | $1,421.00 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041447651 |
| Principal investigator 1 | ModernaTX, Inc. | $1,652.00 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041447667 |
| Principal investigator 1 | ModernaTX, Inc. | $1,334.20 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041447683 |
| Principal investigator 1 | ModernaTX, Inc. | $3,431.40 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041447699 |
| Principal investigator 1 | ModernaTX, Inc. | $2,510.20 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041447713 |
| Principal investigator 1 | ModernaTX, Inc. | $1,652.00 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041447728 |
| Principal investigator 1 | ModernaTX, Inc. | $1,652.00 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041447743 |
| Principal investigator 1 | ModernaTX, Inc. | $1,334.20 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041447759 |
| Principal investigator 1 | ModernaTX, Inc. | $2,510.20 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041447775 |
| Principal investigator 1 | ModernaTX, Inc. | $1,652.00 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041447793 |
| Principal investigator 1 | ModernaTX, Inc. | $1,421.00 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041447811 |
| Principal investigator 1 | ModernaTX, Inc. | $2,510.20 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041447825 |
| Principal investigator 1 | ModernaTX, Inc. | $1,652.00 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041447841 |
| Principal investigator 1 | ModernaTX, Inc. | $1,652.00 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041447857 |
| Principal investigator 1 | ModernaTX, Inc. | $2,336.60 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041447871 |
| Principal investigator 1 | ModernaTX, Inc. | $3,431.40 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041447885 |
| Principal investigator 1 | ModernaTX, Inc. | $1,334.20 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041447903 |
| Principal investigator 1 | ModernaTX, Inc. | $1,652.00 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041448963 |
| Principal investigator 1 | ModernaTX, Inc. | $2,510.20 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041448979 |
| Principal investigator 1 | ModernaTX, Inc. | $1,652.00 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041448995 |
| Principal investigator 1 | ModernaTX, Inc. | $3,431.40 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041449011 |
| Principal investigator 1 | ModernaTX, Inc. | $3,431.40 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041449027 |
| Principal investigator 1 | ModernaTX, Inc. | $2,336.60 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041449043 |
| Principal investigator 1 | ModernaTX, Inc. | $1,334.20 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041449060 |
| Principal investigator 1 | ModernaTX, Inc. | $3,431.40 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041449077 |
| Principal investigator 1 | ModernaTX, Inc. | $1,421.00 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041449093 |
| Principal investigator 1 | ModernaTX, Inc. | $1,652.00 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041449109 |
| Principal investigator 1 | ModernaTX, Inc. | $1,334.20 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041449123 |
| Principal investigator 1 | ModernaTX, Inc. | $1,334.20 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041449137 |
| Principal investigator 1 | ModernaTX, Inc. | $1,652.00 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041449151 |
| Principal investigator 1 | ModernaTX, Inc. | $3,431.40 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041449167 |
| Principal investigator 1 | ModernaTX, Inc. | $3,431.40 | 12/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041449181 |
| Principal investigator 1 | Novavax Inc | $70,286.12 | 12/27/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines | No dispute reported | 06/30/2026 | 1055263993 |
| Principal investigator 1 | ModernaTX, Inc. | $750.00 | 12/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041444971 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 12/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041444985 |
| Principal investigator 1 | ModernaTX, Inc. | $1,500.00 | 12/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041444999 |
| Principal investigator 1 | ModernaTX, Inc. | $50.00 | 12/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041445039 |
| Principal investigator 1 | ModernaTX, Inc. | $650.00 | 12/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041445051 |
| Principal investigator 1 | ModernaTX, Inc. | $2,563.00 | 12/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041445063 |
| Principal investigator 1 | ModernaTX, Inc. | $1,000.00 | 12/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041445109 |
| Principal investigator 1 | ModernaTX, Inc. | $310.44 | 12/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041445147 |
| Principal investigator 1 | ModernaTX, Inc. | $66.00 | 12/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041445161 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 12/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041445767 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 12/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041445783 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 12/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041445801 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 12/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041445981 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 12/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041446013 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 12/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041446029 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 12/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041446043 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 12/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041446063 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 12/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041446075 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 12/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041446093 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 12/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041446105 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 12/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041446121 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 12/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041446137 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 12/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041446153 |
| Principal investigator 1 | ModernaTX, Inc. | $1,000.00 | 12/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041446195 |
| Principal investigator 1 | ModernaTX, Inc. | $50.00 | 12/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041446213 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 12/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041446275 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 12/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041446291 |
| Principal investigator 1 | Novo Nordisk AS | $18.00 | 12/26/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1006917863 |
| Principal investigator 1 | Novo Nordisk AS | $18.00 | 12/26/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1006917875 |
| Principal investigator 1 | Novo Nordisk AS | $18.00 | 12/26/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1006917885 |
| Principal investigator 1 | Novo Nordisk AS | $18.00 | 12/26/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1006917895 |
| Principal investigator 1 | Novo Nordisk AS | $18.00 | 12/26/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1006917903 |
| Principal investigator 1 | Novo Nordisk AS | $18.00 | 12/26/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1006917917 |
| Principal investigator 1 | Novo Nordisk AS | $18.00 | 12/26/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1006917927 |
| Principal investigator 1 | Novo Nordisk AS | $18.00 | 12/26/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1006917935 |
| Principal investigator 1 | Novo Nordisk AS | $18.00 | 12/26/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1006917945 |
| Principal investigator 1 | Novo Nordisk AS | $18.00 | 12/26/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007691351 |
| Principal investigator 1 | Novo Nordisk AS | $18.00 | 12/26/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007954889 |
| Principal investigator 1 | Novo Nordisk AS | $18.00 | 12/26/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007954899 |
| Principal investigator 1 | Novo Nordisk AS | $18.00 | 12/26/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007954909 |
| Principal investigator 1 | Novo Nordisk AS | $18.00 | 12/26/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007954919 |
| Principal investigator 1 | Novo Nordisk AS | $18.00 | 12/26/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007954933 |
| Principal investigator 1 | Novo Nordisk AS | $18.00 | 12/26/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007954943 |
| Principal investigator 1 | Novo Nordisk AS | $18.00 | 12/26/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007954955 |
| Principal investigator 1 | Novo Nordisk AS | $18.00 | 12/26/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007954965 |
| Principal investigator 1 | Novo Nordisk AS | $18.00 | 12/26/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007954975 |
| Principal investigator 1 | Novo Nordisk AS | $18.00 | 12/26/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007954985 |
| Principal investigator 1 | Novo Nordisk AS | $18.00 | 12/26/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1008580499 |
| Principal investigator 1 | Novo Nordisk AS | $18.00 | 12/26/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1008580515 |
| Principal investigator 1 | Novo Nordisk AS | $18.00 | 12/26/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1008580533 |
| Principal investigator 1 | Novo Nordisk AS | $18.00 | 12/26/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1008580551 |
| Principal investigator 1 | Novo Nordisk AS | $18.00 | 12/26/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1008580567 |
| Principal investigator 1 | Novo Nordisk AS | $18.00 | 12/26/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1008580585 |
| Principal investigator 1 | Novo Nordisk AS | $18.00 | 12/26/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1009292591 |
| Principal investigator 1 | Novo Nordisk AS | $18.00 | 12/26/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1009292607 |
| Principal investigator 1 | Novo Nordisk AS | $18.00 | 12/26/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1009292625 |
| Principal investigator 1 | Novo Nordisk AS | $18.00 | 12/26/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1009292641 |
| Principal investigator 1 | Novo Nordisk AS | $18.00 | 12/26/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1009292659 |
| Principal investigator 1 | Novo Nordisk AS | $18.00 | 12/26/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1009292677 |
| Principal investigator 1 | Novo Nordisk AS | $18.00 | 12/26/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1009292693 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,263.00 | 12/22/2023 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | 70033093AFL3002 | No dispute reported | 06/30/2026 | 986108225 |
| Principal investigator 1 | ModernaTX, Inc. | $425.00 | 12/22/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults | No dispute reported | 06/30/2026 | 1041448899 |
| Principal investigator 1 | ModernaTX, Inc. | $25.00 | 12/22/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults | No dispute reported | 06/30/2026 | 1041448913 |
| Principal investigator 1 | ModernaTX, Inc. | $25.00 | 12/22/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults | No dispute reported | 06/30/2026 | 1041448931 |
| Principal investigator 1 | ModernaTX, Inc. | $225.00 | 12/22/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults | No dispute reported | 06/30/2026 | 1041448947 |
| Principal investigator 1 | ModernaTX, Inc. | $150,161.62 | 12/22/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older | No dispute reported | 06/30/2026 | 1041451037 |
| Principal investigator 1 | Janssen Research & Development, LLC | $21,284.00 | 12/20/2023 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 986108203 |
| Principal investigator 1 | Novo Nordisk AS | $650.00 | 12/20/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007691339 |
| Principal investigator 1 | Novo Nordisk AS | $527.08 | 12/18/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007691325 |
| Principal investigator 1 | IBSA Institut Biochimique SA | $2,809.78 | 12/15/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH- DELAND, LLC DBA ACCEL RESEARCH SITES | 18US-FHp04/A multi-center, prospective, open-label, controlled study of the pharmacokinetics and safety of the LicartTM topical system in pediatric and adult participants with minor soft tissue injuries | No dispute reported | 06/30/2026 | 1005352019 |
| Principal investigator 1 | Janssen Research & Development, LLC | $500.00 | 12/15/2023 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 986108201 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,283.00 | 12/15/2023 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | 70033093AFL3002 | No dispute reported | 06/30/2026 | 986108229 |
| Principal investigator 1 | ModernaTX, Inc. | $2,262.87 | 12/14/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1041444063 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 12/14/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041444077 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 12/14/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041444091 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 12/14/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041444173 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 12/14/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041444187 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 12/14/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041444199 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 12/14/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041444213 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 12/14/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041444229 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 12/14/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041444255 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 12/14/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041444267 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 12/14/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041444281 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 12/14/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041444295 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 12/14/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041444309 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 12/14/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041444323 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 12/14/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041444337 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 12/14/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041444351 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 12/14/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041444365 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 12/14/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041444379 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 12/14/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041444393 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 12/14/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041444405 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 12/14/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041444419 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 12/14/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041444433 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 12/14/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041444443 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 12/14/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041444457 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 12/14/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041444471 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 12/14/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041444485 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 12/14/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041444499 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 12/14/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041444513 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 12/14/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041444527 |
| Principal investigator 1 | ModernaTX, Inc. | $2,262.87 | 12/14/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1041444541 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 12/14/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041444571 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 12/14/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041444585 |
| Principal investigator 1 | ModernaTX, Inc. | $2,262.87 | 12/14/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1041444596 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 12/14/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041444611 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 12/14/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041444625 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 12/14/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041444639 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 12/14/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041444651 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 12/14/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041444677 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 12/14/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041444719 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 12/14/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041444743 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 12/14/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041444759 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 12/14/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041444775 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 12/14/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041444783 |
| Principal investigator 1 | ModernaTX, Inc. | $2,262.87 | 12/14/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1041444797 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 12/14/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041444807 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 12/14/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041444819 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 12/14/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041444831 |
| Principal investigator 1 | ModernaTX, Inc. | $2,262.87 | 12/14/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1041444845 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 12/14/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041444865 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 12/14/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041446168 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 12/14/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041446179 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 12/14/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041446229 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 12/14/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041446241 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 12/14/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041446259 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 12/14/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041446305 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 12/14/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041446319 |
| Principal investigator 1 | ModernaTX, Inc. | $198.00 | 12/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041444103 |
| Principal investigator 1 | ModernaTX, Inc. | $63.36 | 12/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041444117 |
| Principal investigator 1 | ModernaTX, Inc. | $1,913.28 | 12/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041444131 |
| Principal investigator 1 | ModernaTX, Inc. | $1,797.36 | 12/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041444145 |
| Principal investigator 1 | ModernaTX, Inc. | $66.00 | 12/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041444159 |
| Principal investigator 1 | ModernaTX, Inc. | $198.00 | 12/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041444243 |
| Principal investigator 1 | ModernaTX, Inc. | $198.00 | 12/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041444553 |
| Principal investigator 1 | ModernaTX, Inc. | $198.00 | 12/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041444665 |
| Principal investigator 1 | ModernaTX, Inc. | $63.36 | 12/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041444691 |
| Principal investigator 1 | ModernaTX, Inc. | $63.36 | 12/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041444705 |
| Principal investigator 1 | ModernaTX, Inc. | $63.36 | 12/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041444729 |
| Principal investigator 1 | ModernaTX, Inc. | $63.36 | 12/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041444853 |
| Principal investigator 1 | ModernaTX, Inc. | $63.36 | 12/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041444879 |
| Principal investigator 1 | ModernaTX, Inc. | $198.00 | 12/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041444889 |
| Principal investigator 1 | ModernaTX, Inc. | $1,200.00 | 12/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older | No dispute reported | 06/30/2026 | 1041451003 |
| Principal investigator 1 | ModernaTX, Inc. | $1,394.55 | 12/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults | No dispute reported | 06/30/2026 | 1041451071 |
| Principal investigator 1 | ModernaTX, Inc. | $21,684.51 | 12/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults | No dispute reported | 06/30/2026 | 1041451087 |
| Principal investigator 1 | ModernaTX, Inc. | $23.00 | 12/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older | No dispute reported | 06/30/2026 | 1041452277 |
| Principal investigator 1 | Novavax Inc | $5,065.00 | 12/13/2023 | Non-covered Recipient Entity TEXAS CENTER FOR DRUG DEVELOPMENT INC | A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) | No dispute reported | 06/30/2026 | 1055265011 |
| Principal investigator 1 | Janssen Research & Development, LLC | $276.00 | 12/07/2023 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 986108185 |
| Principal investigator 1 | Janssen Research & Development, LLC | $110.00 | 12/07/2023 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 986108187 |
| Principal investigator 1 | Janssen Research & Development, LLC | $785.00 | 12/07/2023 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 986108189 |
| Principal investigator 1 | Janssen Research & Development, LLC | $589.00 | 12/07/2023 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 986108191 |
| Principal investigator 1 | Janssen Research & Development, LLC | $160.00 | 12/07/2023 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 986108193 |
| Principal investigator 1 | Janssen Research & Development, LLC | $37.00 | 12/07/2023 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 986108195 |
| Principal investigator 1 | Janssen Research & Development, LLC | $110.00 | 12/07/2023 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 986108197 |
| Principal investigator 1 | Janssen Research & Development, LLC | $41.00 | 12/07/2023 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 986108199 |
| Principal investigator 1 | UCB SA | $1,428.04 | 12/06/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES NETWORK - DELAND CLINICAL RESEARCH UNIT | A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND REPEAT-DOSE (PART B, PARTICIPANT-, INVESTIGATOR-, AND SPONSOR-BLIND) STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY (PART B ONLY) OF UCB1381 IN HEALTHY STUDY PARTICIPANTS (PART A) AND IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (PART B) | No dispute reported | 06/30/2026 | 1059101691 |
| Principal investigator 1 | ModernaTX, Inc. | $3,000.00 | 12/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older | No dispute reported | 06/30/2026 | 1041448883 |
| Principal investigator 1 | Novavax Inc | $146,563.15 | 11/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines | No dispute reported | 06/30/2026 | 1055261065 |
| Principal investigator 1 | Novo Nordisk AS | $18.84 | 11/29/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007691243 |
| Principal investigator 1 | Novo Nordisk AS | $18.84 | 11/29/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007691255 |
| Principal investigator 1 | Novo Nordisk AS | $18.84 | 11/29/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007691267 |
| Principal investigator 1 | Novo Nordisk AS | $18.84 | 11/29/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007691281 |
| Principal investigator 1 | Novo Nordisk AS | $18.84 | 11/29/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007929931 |
| Principal investigator 1 | Janssen Research & Development, LLC | $14,127.00 | 11/28/2023 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 986108223 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 11/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041442791 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 11/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041442805 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 11/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041442819 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 11/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041442833 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 11/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041442847 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 11/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041442861 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 11/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041442875 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 11/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041442887 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 11/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041442901 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 11/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041442915 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 11/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041442929 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 11/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041442941 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 11/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041442955 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 11/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041442983 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 11/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041442995 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 11/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041443023 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 11/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041443037 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 11/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041443049 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 11/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041443063 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 11/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041443075 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 11/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041443087 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 11/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041443101 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 11/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041443115 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 11/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041443129 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 11/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041443141 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 11/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041443155 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 11/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041443167 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 11/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041443181 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 11/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041443195 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 11/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041443207 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 11/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041443221 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 11/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041443235 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 11/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041443249 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 11/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041443263 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 11/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041443275 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 11/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041443289 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 11/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041443331 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 11/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041443345 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 11/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041443357 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 11/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041443369 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 11/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041443383 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 11/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041443399 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 11/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041443413 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 11/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041443427 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 11/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041443443 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 11/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041443457 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 11/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041443469 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 11/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041443481 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 11/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041443493 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 11/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041443507 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 11/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041443521 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 11/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041443549 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 11/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041443561 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 11/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041443575 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 11/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041443589 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 11/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041443603 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 11/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041443617 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 11/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041443633 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 11/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041443645 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 11/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041443657 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 11/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041443671 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 11/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041443685 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 11/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041443699 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 11/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041443715 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 11/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041443729 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 11/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041443741 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 11/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041443753 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 11/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041443767 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 11/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041443781 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 11/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041443799 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 11/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041443811 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 11/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041443825 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 11/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041443839 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 11/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041443855 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 11/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041443871 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 11/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041443885 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 11/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041443895 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 11/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041443907 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 11/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041443923 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 11/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041443937 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 11/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041443951 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 11/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041443965 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 11/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041443979 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 11/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041444009 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 11/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041444023 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 11/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041444033 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 11/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041444047 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,124.39 | 11/27/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH-DELAND LLC | A PHASE III, OPEN-LABEL, RANDOMIZED, CONTROLLED, MULTI-COUNTRY STUDY T | No dispute reported | 06/30/2026 | 1006257457 |
| Principal investigator 1 | ModernaTX, Inc. | $650.00 | 11/24/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults | No dispute reported | 06/30/2026 | 1041450845 |
| Principal investigator 1 | Janssen Research & Development, LLC | $200.00 | 11/23/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Randomized, Double-blind, Placebo-controlled Phase 1/2a Study for Safety and Immunogenicity Evaluations of various RSV.preF-based Vaccine Formulations in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 986140215 |
| Principal investigator 1 | ModernaTX, Inc. | $3,500.00 | 11/22/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1041443009 |
| Principal investigator 1 | ModernaTX, Inc. | $500.00 | 11/22/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1041443315 |
| Principal investigator 1 | Novo Nordisk AS | $2,109.50 | 11/22/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007691303 |
| Principal investigator 1 | Novo Nordisk AS | $321.50 | 11/22/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007691313 |
| Principal investigator 1 | Novo Nordisk AS | $1,000.00 | 11/22/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9535-4984 | No dispute reported | 06/30/2026 | 1008267745 |
| Principal investigator 1 | Janssen Research & Development, LLC | $78.00 | 11/20/2023 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | 70033093AFL3002 | No dispute reported | 06/30/2026 | 986108233 |
| Principal investigator 1 | Janssen Research & Development, LLC | $260.00 | 11/20/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Randomized, Double-blind, Placebo-controlled Phase 1/2a Study for Safety and Immunogenicity Evaluations of various RSV.preF-based Vaccine Formulations in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 986140211 |
| Principal investigator 1 | ModernaTX, Inc. | $500.00 | 11/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1041443535 |
| Principal investigator 1 | ModernaTX, Inc. | $5,000.00 | 11/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older | No dispute reported | 06/30/2026 | 1041450969 |
| Principal investigator 1 | Janssen Research & Development, LLC | $110.00 | 11/14/2023 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 986108207 |
| Principal investigator 1 | Janssen Research & Development, LLC | $462.00 | 11/14/2023 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 986108209 |
| Principal investigator 1 | Janssen Research & Development, LLC | $78.00 | 11/14/2023 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 986108211 |
| Principal investigator 1 | Janssen Research & Development, LLC | $12.00 | 11/14/2023 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 986108213 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,688.00 | 11/14/2023 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 986108215 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,923.00 | 11/14/2023 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 986108217 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,061.00 | 11/14/2023 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 986108219 |
| Principal investigator 1 | Janssen Research & Development, LLC | $110.00 | 11/14/2023 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 986108221 |
| Principal investigator 1 | ModernaTX, Inc. | $1,284.93 | 11/14/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041442777 |
| Principal investigator 1 | ModernaTX, Inc. | $1,814.50 | 11/14/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041442969 |
| Principal investigator 1 | Janssen Research & Development, LLC | $130.00 | 11/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Randomized, Double-blind, Placebo-controlled Phase 1/2a Study for Safety and Immunogenicity Evaluations of various RSV.preF-based Vaccine Formulations in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 986140213 |
| Principal investigator 1 | Novavax Inc | $2,694.60 | 11/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines | No dispute reported | 06/30/2026 | 1055263991 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,631.59 | 11/08/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH-DELAND LLC | A PHASE III, OPEN-LABEL, RANDOMIZED, CONTROLLED, MULTI-COUNTRY STUDY T | No dispute reported | 06/30/2026 | 1006257445 |
| Principal investigator 1 | Novo Nordisk AS | $19.90 | 11/08/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007929855 |
| Principal investigator 1 | Novo Nordisk AS | $19.90 | 11/08/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007929869 |
| Principal investigator 1 | Novo Nordisk AS | $19.90 | 11/08/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007929879 |
| Principal investigator 1 | Novo Nordisk AS | $19.90 | 11/08/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007929889 |
| Principal investigator 1 | Novo Nordisk AS | $19.90 | 11/08/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007929901 |
| Principal investigator 1 | Novo Nordisk AS | $19.90 | 11/08/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007929911 |
| Principal investigator 1 | Novo Nordisk AS | $19.90 | 11/08/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007929921 |
| Principal investigator 1 | Janssen Research & Development, LLC | $25.00 | 11/03/2023 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 986108205 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $22,515.61 | 11/01/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH-DELAND LLC | A PHASE III, OPEN-LABEL, RANDOMIZED, CONTROLLED, MULTI-COUNTRY STUDY T | No dispute reported | 06/30/2026 | 1006257489 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,250.00 | 11/01/2023 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults | No dispute reported | 06/30/2026 | 986108235 |
| Principal investigator 1 | ModernaTX, Inc. | $20,827.80 | 11/01/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults | No dispute reported | 06/30/2026 | 1041450831 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041440853 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041440867 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041440881 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041440895 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041440911 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041440941 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041440969 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041440983 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041440997 |
| Principal investigator 1 | ModernaTX, Inc. | $700.65 | 10/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1041441013 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041441037 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041441045 |
| Principal investigator 1 | ModernaTX, Inc. | $700.65 | 10/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1041441059 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041441069 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041441079 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041441089 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041441103 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041441119 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041441133 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041441163 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041441177 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041441207 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041441223 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041441237 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041441251 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041441265 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041441280 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041441295 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041441309 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041441367 |
| Principal investigator 1 | ModernaTX, Inc. | $2,053.62 | 10/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1041441383 |
| Principal investigator 1 | ModernaTX, Inc. | $2,053.62 | 10/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1041441395 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041441423 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041441435 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041442213 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041442227 |
| Principal investigator 1 | ModernaTX, Inc. | $700.65 | 10/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1041442241 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041442254 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041442267 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041442283 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041442297 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041442309 |
| Principal investigator 1 | ModernaTX, Inc. | $155.50 | 10/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041442323 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041442337 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041442351 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041442363 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041442377 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041442389 |
| Principal investigator 1 | ModernaTX, Inc. | $2,053.62 | 10/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1041442401 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041442413 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041442425 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041442439 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041442451 |
| Principal investigator 1 | ModernaTX, Inc. | $155.50 | 10/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041442463 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041442477 |
| Principal investigator 1 | ModernaTX, Inc. | $700.65 | 10/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1041442491 |
| Principal investigator 1 | ModernaTX, Inc. | $700.65 | 10/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1041442505 |
| Principal investigator 1 | ModernaTX, Inc. | $2,053.62 | 10/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1041442519 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041442533 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041442549 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041442563 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041442577 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041442591 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041442605 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041442619 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041442635 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041442649 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041442663 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041442677 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041442691 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041442703 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041442719 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041442726 |
| Principal investigator 1 | ModernaTX, Inc. | $2,053.62 | 10/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1041442737 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041442751 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041442765 |
| Principal investigator 1 | Bavarian Nordic A/S | $500.00 | 10/25/2023 | Non-covered Recipient Entity UNIV CLINICAL RESEARCH - DELAND LLC | A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 | No dispute reported | 06/30/2026 | 988695195 |
| Principal investigator 1 | Bavarian Nordic A/S | $1,500.00 | 10/25/2023 | Non-covered Recipient Entity UNIV CLINICAL RESEARCH - DELAND LLC | A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 | No dispute reported | 06/30/2026 | 988695201 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,788.00 | 10/25/2023 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | 70033093AFL3002 | No dispute reported | 06/30/2026 | 986108227 |
| Principal investigator 1 | Novo Nordisk AS | $177.75 | 10/25/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007691291 |
| Principal investigator 1 | ModernaTX, Inc. | $67.00 | 10/24/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1041419455 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $1,000.00 | 10/19/2023 | Non-covered Recipient Entity University Clinical Research,llc Dba Avail Clinical Research,llc | Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1035896263 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 10/18/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041440837 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 10/18/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041440923 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 10/18/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041440955 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 10/18/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041441025 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 10/18/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041441147 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 10/18/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041441191 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 10/18/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041441323 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 10/18/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041441337 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 10/18/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041441353 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 10/18/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041441407 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 10/18/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041441449 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 10/18/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041441465 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 10/18/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041441479 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 10/18/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041441491 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 10/18/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041441505 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 10/18/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041441519 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 10/18/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041441533 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 10/18/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041441547 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 10/18/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041441559 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 10/18/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041441645 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 10/18/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041441659 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 10/18/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041441671 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 10/18/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041441755 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 10/18/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041441771 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 10/18/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041441785 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 10/18/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041441883 |
| Principal investigator 1 | ModernaTX, Inc. | $66.00 | 10/18/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041441919 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 10/18/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041441955 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 10/18/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041441978 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 10/18/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041441991 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 10/18/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041442065 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 10/18/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041442091 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 10/18/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041442105 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 10/18/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041442159 |
| Principal investigator 1 | ModernaTX, Inc. | $22,111.07 | 10/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1/2, Randomized, Observer-blind, Active-Control Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-based Influenza and SARS-CoV-2 Multi-component Vaccines in Healthy Adults | No dispute reported | 06/30/2026 | 1041450877 |
| Principal investigator 1 | Bavarian Nordic A/S | $682.50 | 10/11/2023 | Non-covered Recipient Entity UNIV CLINICAL RESEARCH - DELAND LLC | A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 | No dispute reported | 06/30/2026 | 988695183 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 10/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041439415 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 10/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041439429 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041439445 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041439459 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041439472 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041439485 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041439499 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041439513 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041439527 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041439541 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041439555 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 10/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041439569 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041439597 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 10/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041439615 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041439655 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041439669 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041439711 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 10/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041439723 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041439739 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041439755 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041439771 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041439799 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041439811 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041439827 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041439841 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041439869 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 10/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041439883 |
| Principal investigator 1 | ModernaTX, Inc. | $155.50 | 10/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041439925 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041439939 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041439953 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041439967 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041439981 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041439995 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041440011 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041440039 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 10/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041440063 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041440077 |
| Principal investigator 1 | ModernaTX, Inc. | $155.50 | 10/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041440093 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041440109 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 10/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041440123 |
| Principal investigator 1 | ModernaTX, Inc. | $155.50 | 10/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041440179 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041440211 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041440225 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 10/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041440237 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041440293 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041440307 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041440417 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 10/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041440461 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041440475 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041440503 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041440573 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041440605 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041440621 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041440635 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 10/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041440649 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041440663 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041440677 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 10/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041441571 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041441585 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041441599 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041441617 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041441631 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 10/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041441685 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 10/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041441699 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041441713 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041441727 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041441741 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041441799 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041441813 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041441827 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041441841 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041441855 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041441871 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041441895 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041441909 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041441931 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041441942 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041441969 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 10/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041442003 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041442013 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041442025 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041442039 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041442053 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041442079 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041442117 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041442131 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041442146 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041442171 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 10/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041442185 |
| Principal investigator 1 | Novavax Inc | $305.00 | 10/06/2023 | Non-covered Recipient Entity SANDHILL RESEARCH LLC | A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) | No dispute reported | 06/30/2026 | 1055263083 |
| Principal investigator 1 | ModernaTX, Inc. | $20.25 | 10/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1041439583 |
| Principal investigator 1 | ModernaTX, Inc. | $20.25 | 10/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1041439627 |
| Principal investigator 1 | ModernaTX, Inc. | $4,745.93 | 10/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1041439641 |
| Principal investigator 1 | ModernaTX, Inc. | $4,745.93 | 10/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1041439683 |
| Principal investigator 1 | ModernaTX, Inc. | $20.25 | 10/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1041439699 |
| Principal investigator 1 | ModernaTX, Inc. | $801.90 | 10/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1041439782 |
| Principal investigator 1 | ModernaTX, Inc. | $20.25 | 10/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1041439855 |
| Principal investigator 1 | ModernaTX, Inc. | $20.25 | 10/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1041439897 |
| Principal investigator 1 | ModernaTX, Inc. | $20.25 | 10/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1041439911 |
| Principal investigator 1 | ModernaTX, Inc. | $20.25 | 10/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1041440025 |
| Principal investigator 1 | ModernaTX, Inc. | $64.68 | 10/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041440049 |
| Principal investigator 1 | ModernaTX, Inc. | $801.90 | 10/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1041440139 |
| Principal investigator 1 | ModernaTX, Inc. | $20.25 | 10/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1041440155 |
| Principal investigator 1 | ModernaTX, Inc. | $20.25 | 10/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1041440165 |
| Principal investigator 1 | ModernaTX, Inc. | $20.25 | 10/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1041440193 |
| Principal investigator 1 | ModernaTX, Inc. | $20.25 | 10/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1041440251 |
| Principal investigator 1 | ModernaTX, Inc. | $20.25 | 10/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1041440265 |
| Principal investigator 1 | ModernaTX, Inc. | $20.25 | 10/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1041440279 |
| Principal investigator 1 | ModernaTX, Inc. | $801.90 | 10/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1041440335 |
| Principal investigator 1 | ModernaTX, Inc. | $20.25 | 10/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1041440349 |
| Principal investigator 1 | ModernaTX, Inc. | $20.25 | 10/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1041440363 |
| Principal investigator 1 | ModernaTX, Inc. | $20.25 | 10/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1041440377 |
| Principal investigator 1 | ModernaTX, Inc. | $20.25 | 10/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1041440391 |
| Principal investigator 1 | ModernaTX, Inc. | $20.25 | 10/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1041440405 |
| Principal investigator 1 | ModernaTX, Inc. | $20.25 | 10/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1041440431 |
| Principal investigator 1 | ModernaTX, Inc. | $64.68 | 10/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041440445 |
| Principal investigator 1 | ModernaTX, Inc. | $4,745.93 | 10/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1041440489 |
| Principal investigator 1 | ModernaTX, Inc. | $20.25 | 10/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1041440517 |
| Principal investigator 1 | ModernaTX, Inc. | $20.25 | 10/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1041440531 |
| Principal investigator 1 | ModernaTX, Inc. | $20.25 | 10/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1041440545 |
| Principal investigator 1 | ModernaTX, Inc. | $20.25 | 10/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1041440559 |
| Principal investigator 1 | ModernaTX, Inc. | $20.25 | 10/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1041440587 |
| Principal investigator 1 | ModernaTX, Inc. | $20.25 | 10/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1041440693 |
| Principal investigator 1 | ModernaTX, Inc. | $20.25 | 10/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1041440707 |
| Principal investigator 1 | ModernaTX, Inc. | $20.25 | 10/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1041440719 |
| Principal investigator 1 | ModernaTX, Inc. | $20.25 | 10/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1041440733 |
| Principal investigator 1 | ModernaTX, Inc. | $801.90 | 10/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1041440747 |
| Principal investigator 1 | ModernaTX, Inc. | $4,745.93 | 10/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1041440763 |
| Principal investigator 1 | ModernaTX, Inc. | $20.25 | 10/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1041440778 |
| Principal investigator 1 | ModernaTX, Inc. | $801.90 | 10/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1041440795 |
| Principal investigator 1 | ModernaTX, Inc. | $20.25 | 10/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1041440809 |
| Principal investigator 1 | ModernaTX, Inc. | $20.25 | 10/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1041440823 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,956.22 | 10/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND-DELA | A PHASE III, OPEN-LABEL, RANDOMIZED, CONTROLLED, MULTI-COUNTRY STUDY T | No dispute reported | 06/30/2026 | 1006257483 |
| Principal investigator 1 | Janssen Research & Development, LLC | $12,050.00 | 10/04/2023 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | 70033093AFL3002 | No dispute reported | 06/30/2026 | 986108231 |
| Principal investigator 1 | Averitas Pharma Inc. | $75.00 | 10/03/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN | No dispute reported | 06/30/2026 | 1058764399 |
| Principal investigator 1 | Averitas Pharma Inc. | $128.00 | 10/03/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN | No dispute reported | 06/30/2026 | 1058764401 |
| Principal investigator 1 | Averitas Pharma Inc. | $128.00 | 10/03/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN | No dispute reported | 06/30/2026 | 1058764405 |
| Principal investigator 1 | Averitas Pharma Inc. | $75.00 | 10/03/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN | No dispute reported | 06/30/2026 | 1058764409 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $19,150.00 | 10/02/2023 | Non-covered Recipient Entity Accel Research Sites Deland | MRD PoCP study in NFLD 12 wks | No dispute reported | 06/30/2026 | 1007646755 |
| Principal investigator 1 | ModernaTX, Inc. | $1,000.00 | 10/02/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1041440321 |
| Principal investigator 1 | ModernaTX, Inc. | $115.00 | 10/02/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older | No dispute reported | 06/30/2026 | 1041452229 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,417.00 | 09/28/2023 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 986108161 |
| Principal investigator 1 | Janssen Research & Development, LLC | $210.00 | 09/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Randomized, Double-blind, Placebo-controlled Phase 1/2a Study for Safety and Immunogenicity Evaluations of various RSV.preF-based Vaccine Formulations in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 986140209 |
| Principal investigator 1 | Bavarian Nordic A/S | $500.00 | 09/27/2023 | Non-covered Recipient Entity UNIV CLINICAL RESEARCH - DELAND LLC | A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 | No dispute reported | 06/30/2026 | 988695115 |
| Principal investigator 1 | Bavarian Nordic A/S | $3,280.50 | 09/27/2023 | Non-covered Recipient Entity UNIV CLINICAL RESEARCH - DELAND LLC | A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 | No dispute reported | 06/30/2026 | 988695121 |
| Principal investigator 1 | Bavarian Nordic A/S | $1,093.50 | 09/27/2023 | Non-covered Recipient Entity UNIV CLINICAL RESEARCH - DELAND LLC | A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 | No dispute reported | 06/30/2026 | 988695127 |
| Principal investigator 1 | Bavarian Nordic A/S | $2,187.00 | 09/27/2023 | Non-covered Recipient Entity UNIV CLINICAL RESEARCH - DELAND LLC | A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 | No dispute reported | 06/30/2026 | 988695133 |
| Principal investigator 1 | Bavarian Nordic A/S | $4,374.00 | 09/27/2023 | Non-covered Recipient Entity UNIV CLINICAL RESEARCH - DELAND LLC | A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 | No dispute reported | 06/30/2026 | 988695139 |
| Principal investigator 1 | Bavarian Nordic A/S | $455.00 | 09/27/2023 | Non-covered Recipient Entity UNIV CLINICAL RESEARCH - DELAND LLC | A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 | No dispute reported | 06/30/2026 | 988695145 |
| Principal investigator 1 | Bavarian Nordic A/S | $682.50 | 09/27/2023 | Non-covered Recipient Entity UNIV CLINICAL RESEARCH - DELAND LLC | A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 | No dispute reported | 06/30/2026 | 988695151 |
| Principal investigator 1 | Bavarian Nordic A/S | $910.00 | 09/27/2023 | Non-covered Recipient Entity UNIV CLINICAL RESEARCH - DELAND LLC | A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 | No dispute reported | 06/30/2026 | 988695159 |
| Principal investigator 1 | Bavarian Nordic A/S | $817.50 | 09/27/2023 | Non-covered Recipient Entity UNIV CLINICAL RESEARCH - DELAND LLC | A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 | No dispute reported | 06/30/2026 | 988695165 |
| Principal investigator 1 | Bavarian Nordic A/S | $3,280.50 | 09/27/2023 | Non-covered Recipient Entity UNIV CLINICAL RESEARCH - DELAND LLC | A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 | No dispute reported | 06/30/2026 | 988695219 |
| Principal investigator 1 | Bavarian Nordic A/S | $2,187.00 | 09/27/2023 | Non-covered Recipient Entity UNIV CLINICAL RESEARCH - DELAND LLC | A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 | No dispute reported | 06/30/2026 | 988695225 |
| Principal investigator 1 | Bavarian Nordic A/S | $1,093.50 | 09/27/2023 | Non-covered Recipient Entity UNIV CLINICAL RESEARCH - DELAND LLC | A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 | No dispute reported | 06/30/2026 | 988695231 |
| Principal investigator 1 | Bavarian Nordic A/S | $1,093.50 | 09/27/2023 | Non-covered Recipient Entity UNIV CLINICAL RESEARCH - DELAND LLC | A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 | No dispute reported | 06/30/2026 | 988695237 |
| Principal investigator 1 | Bavarian Nordic A/S | $1,093.50 | 09/27/2023 | Non-covered Recipient Entity UNIV CLINICAL RESEARCH - DELAND LLC | A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 | No dispute reported | 06/30/2026 | 988695243 |
| Principal investigator 1 | Bavarian Nordic A/S | $682.50 | 09/27/2023 | Non-covered Recipient Entity UNIV CLINICAL RESEARCH - DELAND LLC | A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 | No dispute reported | 06/30/2026 | 988695251 |
| Principal investigator 1 | Bavarian Nordic A/S | $455.00 | 09/27/2023 | Non-covered Recipient Entity UNIV CLINICAL RESEARCH - DELAND LLC | A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 | No dispute reported | 06/30/2026 | 988695255 |
| Principal investigator 1 | ModernaTX, Inc. | $346,522.23 | 09/27/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041450765 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,710.00 | 09/26/2023 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults | No dispute reported | 06/30/2026 | 986108181 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $33,392.01 | 09/22/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH-DELAND LLC | A PHASE III, OPEN-LABEL, RANDOMIZED, CONTROLLED, MULTI-COUNTRY STUDY T | No dispute reported | 06/30/2026 | 1006257475 |
| Principal investigator 1 | Novo Nordisk AS | $1,846.84 | 09/22/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007929835 |
| Principal investigator 1 | Novo Nordisk AS | $859.10 | 09/22/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007929845 |
| Principal investigator 1 | Novo Nordisk AS | $1,000.00 | 09/22/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9535-4984 | No dispute reported | 06/30/2026 | 1008267731 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,500.00 | 09/20/2023 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults | No dispute reported | 06/30/2026 | 986108179 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,500.00 | 09/18/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Randomized, Double-blind, Placebo-controlled Phase 1/2a Study for Safety and Immunogenicity Evaluations of various RSV.preF-based Vaccine Formulations in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 986140207 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $500.00 | 09/15/2023 | Non-covered Recipient Entity University Clinical Research,llc Dba Avail Clinical Research,llc | Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1035895663 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $650.00 | 09/15/2023 | Non-covered Recipient Entity University Clinical Research,llc Dba Avail Clinical Research,llc | Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1035895699 |
| Principal investigator 1 | Chiesi USA, Inc. | $2,524.00 | 09/14/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) | No dispute reported | 06/30/2026 | 1051607033 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6.00 | 09/14/2023 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 986108155 |
| Principal investigator 1 | Janssen Research & Development, LLC | $250.00 | 09/14/2023 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 986108157 |
| Principal investigator 1 | Janssen Research & Development, LLC | $110.00 | 09/14/2023 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 986108159 |
| Principal investigator 1 | Novavax Inc | $138.00 | 09/12/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 | No dispute reported | 06/30/2026 | 1055260073 |
| Principal investigator 1 | Amgen Inc. | $7,086.24 | 09/11/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES ACR | AMG 451 DDI/Atopic Dermatitis | No dispute reported | 06/30/2026 | 1029648211 |
| Principal investigator 1 | PFIZER INC. | $915.00 | 09/09/2023 | Non-covered Recipient Entity University Clinical Research DeLand LLC | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1046405961 |
| Principal investigator 1 | Janssen Research & Development, LLC | $20.00 | 09/07/2023 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 986108153 |
| Principal investigator 1 | ModernaTX, Inc. | $4,745.93 | 09/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1041439389 |
| Principal investigator 1 | ModernaTX, Inc. | $20.25 | 09/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1041439403 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,273.00 | 09/06/2023 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 986108151 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,280.00 | 09/06/2023 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 986108169 |
| Principal investigator 1 | Eli Lilly and Company | $29,442.45 | 09/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A PARALLEL-GROUP SINGLE-DOSE PHASE 1 OPEN-LABEL STUDY TO INVESTIGATE THE PHARMACOKINETICS OF LY3437943 IN PARTICIPANTS WITH HEPATIC IMPAIRMENT COMPARED WITH HEALTHY PARTICIPANTS | No dispute reported | 06/30/2026 | 1038151675 |
| Principal investigator 1 | Averitas Pharma Inc. | $128.00 | 09/01/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN | No dispute reported | 06/30/2026 | 1058764395 |
| Principal investigator 1 | Averitas Pharma Inc. | $150.00 | 09/01/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN | No dispute reported | 06/30/2026 | 1058764397 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,317.27 | 09/01/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH-DELAND LLC | A PHASE III, OPEN-LABEL, RANDOMIZED, CONTROLLED, MULTI-COUNTRY STUDY T | No dispute reported | 06/30/2026 | 1006257469 |
| Principal investigator 1 | Janssen Pharmaceuticals, Inc | $504.00 | 09/01/2023 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 986093521 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $6,403.98 | 09/01/2023 | Non-covered Recipient Entity University Clinical Research,llc Dba Avail Clinical Research,llc | Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1035895931 |
| Principal investigator 1 | Janssen Research & Development, LLC | $15,131.00 | 08/31/2023 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 986108167 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $1,000.00 | 08/29/2023 | Non-covered Recipient Entity University Clinical Research,llc Dba Avail Clinical Research,llc | Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1035895797 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $1,000.00 | 08/29/2023 | Non-covered Recipient Entity University Clinical Research,llc Dba Avail Clinical Research,llc | Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1035895807 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $6,403.98 | 08/29/2023 | Non-covered Recipient Entity University Clinical Research,llc Dba Avail Clinical Research,llc | Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1035895917 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $63,952.38 | 08/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH-DELAND LLC | A PHASE III, OPEN-LABEL, RANDOMIZED, CONTROLLED, MULTI-COUNTRY STUDY T | No dispute reported | 06/30/2026 | 1006257463 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 08/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041438077 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 08/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041438089 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 08/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041438133 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 08/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041438175 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 08/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041438259 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 08/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041438289 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 08/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041438305 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 08/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041438389 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 08/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041438473 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 08/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041438487 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 08/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041438531 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 08/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041438545 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 08/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041438559 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 08/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041438574 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 08/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041438589 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 08/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041438645 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 08/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041438659 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 08/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041438675 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 08/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041438717 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 08/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041438731 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 08/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041438748 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 08/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041439076 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 08/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041439253 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $100.00 | 08/28/2023 | Non-covered Recipient Entity University Clinical Research,llc Dba Avail Clinical Research,llc | Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1035895625 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $320.76 | 08/28/2023 | Non-covered Recipient Entity University Clinical Research,llc Dba Avail Clinical Research,llc | Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1035895638 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $1,187.34 | 08/28/2023 | Non-covered Recipient Entity University Clinical Research,llc Dba Avail Clinical Research,llc | Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1035895709 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $1,187.34 | 08/28/2023 | Non-covered Recipient Entity University Clinical Research,llc Dba Avail Clinical Research,llc | Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1035895723 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $1,187.34 | 08/28/2023 | Non-covered Recipient Entity University Clinical Research,llc Dba Avail Clinical Research,llc | Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1035895735 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $1,187.34 | 08/28/2023 | Non-covered Recipient Entity University Clinical Research,llc Dba Avail Clinical Research,llc | Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1035895763 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $2,245.32 | 08/28/2023 | Non-covered Recipient Entity University Clinical Research,llc Dba Avail Clinical Research,llc | Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1035895785 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $2,374.68 | 08/28/2023 | Non-covered Recipient Entity University Clinical Research,llc Dba Avail Clinical Research,llc | Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1035895819 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $3,288.12 | 08/28/2023 | Non-covered Recipient Entity University Clinical Research,llc Dba Avail Clinical Research,llc | Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1035895845 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $3,562.02 | 08/28/2023 | Non-covered Recipient Entity University Clinical Research,llc Dba Avail Clinical Research,llc | Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1035895893 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $3,562.02 | 08/28/2023 | Non-covered Recipient Entity University Clinical Research,llc Dba Avail Clinical Research,llc | Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1035895905 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $9,906.47 | 08/28/2023 | Non-covered Recipient Entity University Clinical Research,llc Dba Avail Clinical Research,llc | Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1035895979 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $11,873.40 | 08/28/2023 | Non-covered Recipient Entity University Clinical Research,llc Dba Avail Clinical Research,llc | Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1035896005 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $1,187.34 | 08/28/2023 | Non-covered Recipient Entity University Clinical Research Dela LLC | Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1035915423 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 08/25/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041438017 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 08/25/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041438031 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 08/25/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041438045 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 08/25/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041438061 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 08/25/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041438119 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 08/25/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041438147 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 08/25/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041438161 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 08/25/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041438203 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 08/25/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041438217 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 08/25/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041438231 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 08/25/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041438245 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 08/25/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041438275 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 08/25/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041438319 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 08/25/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041438333 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 08/25/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041438347 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 08/25/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041438375 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 08/25/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041438403 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 08/25/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041438417 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 08/25/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041438433 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 08/25/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041438447 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 08/25/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041438459 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 08/25/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041438517 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 08/25/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041438617 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 08/25/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041438631 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 08/25/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041438689 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 08/25/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041438703 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 08/25/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041438791 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 08/25/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041438807 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 08/25/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041438821 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 08/25/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041438865 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 08/25/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041438991 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 08/25/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041439005 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 08/25/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041439019 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 08/25/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041439033 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 08/25/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041439047 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 08/25/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041439061 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 08/25/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041439195 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 08/25/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041439209 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 08/25/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041439223 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 08/25/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041439237 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 08/25/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041439347 |
| Principal investigator 1 | ModernaTX, Inc. | $550.00 | 08/25/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041448535 |
| Principal investigator 1 | PFIZER INC. | $528,337.50 | 08/24/2023 | Non-covered Recipient Entity University Clinical Research DeLand LLC | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1046402559 |
| Principal investigator 1 | Janssen Research & Development, LLC | $10,758.00 | 08/23/2023 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants | No dispute reported | 06/30/2026 | 986108177 |
| Principal investigator 1 | ModernaTX, Inc. | $250.00 | 08/23/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041438503 |
| Principal investigator 1 | ModernaTX, Inc. | $250.00 | 08/23/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041438779 |
| Principal investigator 1 | ModernaTX, Inc. | $16,400.00 | 08/23/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older | No dispute reported | 06/30/2026 | 1041450939 |
| Principal investigator 1 | Averitas Pharma Inc. | $128.00 | 08/18/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN | No dispute reported | 06/30/2026 | 1058764391 |
| Principal investigator 1 | Averitas Pharma Inc. | $75.00 | 08/18/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN | No dispute reported | 06/30/2026 | 1058764393 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,906.03 | 08/18/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Randomized, Double-blind, Placebo-controlled Phase 1/2a Study for Safety and Immunogenicity Evaluations of various RSV.preF-based Vaccine Formulations in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 986140201 |
| Principal investigator 1 | Janssen Research & Development, LLC | $100.00 | 08/18/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Randomized, Double-blind, Placebo-controlled Phase 1/2a Study for Safety and Immunogenicity Evaluations of various RSV.preF-based Vaccine Formulations in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 986140203 |
| Principal investigator 1 | ModernaTX, Inc. | $217.80 | 08/18/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041437989 |
| Principal investigator 1 | ModernaTX, Inc. | $297.00 | 08/18/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041438003 |
| Principal investigator 1 | ModernaTX, Inc. | $198.00 | 08/18/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041438103 |
| Principal investigator 1 | ModernaTX, Inc. | $217.80 | 08/18/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041438189 |
| Principal investigator 1 | ModernaTX, Inc. | $118.80 | 08/18/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041438361 |
| Principal investigator 1 | ModernaTX, Inc. | $64.68 | 08/18/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041438762 |
| Principal investigator 1 | ModernaTX, Inc. | $118.80 | 08/18/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041438851 |
| Principal investigator 1 | ModernaTX, Inc. | $297.00 | 08/18/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041438963 |
| Principal investigator 1 | ModernaTX, Inc. | $64.68 | 08/18/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041439167 |
| Principal investigator 1 | ModernaTX, Inc. | $297.00 | 08/18/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041439181 |
| Principal investigator 1 | ModernaTX, Inc. | $64.68 | 08/18/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041439305 |
| Principal investigator 1 | ModernaTX, Inc. | $198.00 | 08/18/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041439317 |
| Principal investigator 1 | ModernaTX, Inc. | $118.80 | 08/18/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041439333 |
| Principal investigator 1 | Novavax Inc | $1,800.00 | 08/18/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) | No dispute reported | 06/30/2026 | 1055265019 |
| Principal investigator 1 | Novo Nordisk AS | $1,870.83 | 08/18/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007822203 |
| Principal investigator 1 | ModernaTX, Inc. | $2,149.27 | 08/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1041438837 |
| Principal investigator 1 | Janssen Pharmaceuticals, Inc | $50.00 | 08/16/2023 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 986093525 |
| Principal investigator 1 | ModernaTX, Inc. | $1,550.00 | 08/16/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults | No dispute reported | 06/30/2026 | 1041450815 |
| Principal investigator 1 | ModernaTX, Inc. | $138.00 | 08/16/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older | No dispute reported | 06/30/2026 | 1041452261 |
| Recipient | Novavax Inc | $166.57 | 08/16/2023 | Covered Recipient Physician | A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines | No dispute reported | 06/30/2026 | 1055258319 |
| Recipient | Novavax Inc | $182.03 | 08/16/2023 | Covered Recipient Physician | A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines | No dispute reported | 06/30/2026 | 1055258443 |
| Recipient | Novavax Inc | $190.97 | 08/16/2023 | Covered Recipient Physician | A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines | No dispute reported | 06/30/2026 | 1055258635 |
| Recipient | Novavax Inc | $353.70 | 08/16/2023 | Covered Recipient Physician | A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines | No dispute reported | 06/30/2026 | 1055258637 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $83,783.15 | 08/14/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH-DELAND LLC | A PHASE III, OPEN-LABEL, RANDOMIZED, CONTROLLED, MULTI-COUNTRY STUDY T | No dispute reported | 06/30/2026 | 1006257439 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,183.00 | 08/11/2023 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | 70033093AFL3002 | No dispute reported | 06/30/2026 | 986108171 |
| Principal investigator 1 | ModernaTX, Inc. | $2,544.15 | 08/11/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older | No dispute reported | 06/30/2026 | 1041448721 |
| Principal investigator 1 | PFIZER INC. | $150.00 | 08/11/2023 | Non-covered Recipient Entity University Clinical Research DeLand LLC | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1046420119 |
| Principal investigator 1 | Novavax Inc | $4,100.00 | 08/10/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) | No dispute reported | 06/30/2026 | 1055259111 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 08/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041437011 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 08/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041437025 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 08/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041437041 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 08/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041437055 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 08/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041437069 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 08/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041437083 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 08/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041437097 |
| Principal investigator 1 | ModernaTX, Inc. | $500.00 | 08/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1041437111 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 08/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041437125 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 08/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041437139 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 08/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041437153 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 08/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041437167 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 08/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041437181 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 08/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041437195 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 08/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041437207 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 08/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041437221 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 08/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041437235 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 08/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041437249 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 08/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041437263 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 08/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041437277 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 08/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041437291 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 08/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041437305 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 08/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041437319 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 08/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041437333 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 08/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041437347 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 08/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041437363 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 08/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041437379 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 08/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041437393 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 08/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041437405 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 08/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041437419 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 08/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041437429 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 08/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041437443 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 08/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041437460 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 08/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041437472 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 08/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041437487 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 08/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041437497 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 08/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041437511 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 08/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041437525 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 08/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041437537 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 08/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041437551 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 08/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041437563 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 08/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041437573 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 08/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041437583 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 08/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041437597 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 08/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041437611 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 08/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041437629 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 08/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041437647 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 08/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041437663 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 08/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041437677 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 08/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041437691 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 08/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041437705 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 08/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041437719 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 08/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041437735 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 08/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041437749 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 08/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041437763 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 08/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041437777 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 08/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041437791 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 08/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041437805 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 08/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041437819 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 08/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041437837 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 08/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041437849 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 08/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041437863 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 08/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041437877 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 08/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041437893 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 08/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041437905 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 08/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041437919 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 08/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041437933 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 08/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041437945 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 08/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041437959 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 08/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041437975 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 08/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041438879 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 08/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041438893 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 08/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041438907 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 08/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041438921 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 08/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041438935 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 08/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041438949 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 08/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041438977 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 08/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041439091 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 08/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041439107 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 08/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041439123 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 08/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041439137 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 08/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041439151 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 08/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041439265 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 08/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041439277 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 08/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041439291 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 08/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041439361 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 08/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041439375 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $2,000.00 | 08/07/2023 | Non-covered Recipient Entity University Clinical Research,llc Dba Avail Clinical Research,llc | Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1035895651 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $8,500.00 | 08/07/2023 | Non-covered Recipient Entity University Clinical Research,llc Dba Avail Clinical Research,llc | Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1035895747 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $500.00 | 08/07/2023 | Non-covered Recipient Entity University Clinical Research,llc Dba Avail Clinical Research,llc | Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1035896053 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $1,000.00 | 08/07/2023 | Non-covered Recipient Entity University Clinical Research,llc Dba Avail Clinical Research,llc | Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1035896063 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $12,008.90 | 08/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH-DELAND LLC | A PHASE III, OPEN-LABEL, RANDOMIZED, CONTROLLED, MULTI-COUNTRY STUDY T | No dispute reported | 06/30/2026 | 1006257451 |
| Principal investigator 1 | Janssen Research & Development, LLC | $475.00 | 08/04/2023 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants | No dispute reported | 06/30/2026 | 986108175 |
| Principal investigator 1 | ModernaTX, Inc. | $1,000.00 | 08/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults | No dispute reported | 06/30/2026 | 1041448613 |
| Principal investigator 1 | ModernaTX, Inc. | $1,500.00 | 08/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults | No dispute reported | 06/30/2026 | 1041448629 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,320.00 | 08/03/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Randomized, Double-blind, Placebo-controlled Phase 1/2a Study for Safety and Immunogenicity Evaluations of various RSV.preF-based Vaccine Formulations in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 986140205 |
| Principal investigator 1 | Janssen Pharmaceuticals, Inc | $31,843.00 | 08/02/2023 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 986093523 |
| Principal investigator 1 | Janssen Research & Development, LLC | $39,095.00 | 08/02/2023 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults | No dispute reported | 06/30/2026 | 986108183 |
| Principal investigator 1 | ModernaTX, Inc. | $2,000.00 | 08/02/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults | No dispute reported | 06/30/2026 | 1041448597 |
| Principal investigator 1 | ModernaTX, Inc. | $42,462.29 | 08/02/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older | No dispute reported | 06/30/2026 | 1041450925 |
| Principal investigator 1 | Janssen Research & Development, LLC | $960.00 | 07/31/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Randomized, Double-blind, Placebo-controlled Phase 1/2a Study for Safety and Immunogenicity Evaluations of various RSV.preF-based Vaccine Formulations in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 986140193 |
| Principal investigator 1 | Janssen Research & Development, LLC | $250.00 | 07/31/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Randomized, Double-blind, Placebo-controlled Phase 1/2a Study for Safety and Immunogenicity Evaluations of various RSV.preF-based Vaccine Formulations in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 986140199 |
| Principal investigator 1 | Novo Nordisk AS | $14.99 | 07/31/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1008472795 |
| Principal investigator 1 | Novo Nordisk AS | $14.99 | 07/31/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1008472809 |
| Principal investigator 1 | Novo Nordisk AS | $14.99 | 07/31/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1008472823 |
| Principal investigator 1 | Novo Nordisk AS | $14.99 | 07/31/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1008472839 |
| Principal investigator 1 | Novo Nordisk AS | $14.99 | 07/31/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1008472853 |
| Principal investigator 1 | Novo Nordisk AS | $14.99 | 07/31/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1008472867 |
| Principal investigator 1 | ModernaTX, Inc. | $3,000.00 | 07/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults | No dispute reported | 06/30/2026 | 1041448581 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,500.00 | 07/27/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Randomized, Double-blind, Placebo-controlled Phase 1/2a Study for Safety and Immunogenicity Evaluations of various RSV.preF-based Vaccine Formulations in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 986140189 |
| Principal investigator 1 | Janssen Research & Development, LLC | $450.00 | 07/27/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Randomized, Double-blind, Placebo-controlled Phase 1/2a Study for Safety and Immunogenicity Evaluations of various RSV.preF-based Vaccine Formulations in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 986140191 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,000.00 | 07/27/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Randomized, Double-blind, Placebo-controlled Phase 1/2a Study for Safety and Immunogenicity Evaluations of various RSV.preF-based Vaccine Formulations in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 986140197 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,535.13 | 07/26/2023 | Non-covered Recipient Entity Accel Research Sites Deland | MRD PoCP study in NFLD 12 wks | No dispute reported | 06/30/2026 | 1007644195 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $6,700.00 | 07/26/2023 | Non-covered Recipient Entity Accel Research Sites-DeLand Clinical Research Unit | A Phase 3, Multicenter, Open-Label Study to Evaluate the Safety and Immunogenicity of 2-dose Regimens of 9vHPV and mRNA-1273 SARS-CoV-2 Vaccines Where the First Dose of Each Vaccine Are Given Concomitantly in Boys and Girls 9 to 11 Years of Age | No dispute reported | 06/30/2026 | 1042488569 |
| Principal investigator 1 | ModernaTX, Inc. | $297.00 | 07/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older | No dispute reported | 06/30/2026 | 1041448707 |
| Principal investigator 1 | Novavax Inc | $3,174.00 | 07/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 | No dispute reported | 06/30/2026 | 1055259109 |
| Principal investigator 1 | Novo Nordisk AS | $3,180.64 | 07/24/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007822197 |
| Principal investigator 1 | Janssen Pharmaceuticals, Inc | $2,965.00 | 07/21/2023 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 986093519 |
| Principal investigator 1 | Janssen Research & Development, LLC | $250.00 | 07/21/2023 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants | No dispute reported | 06/30/2026 | 986108173 |
| Principal investigator 1 | Novo Nordisk AS | $10.56 | 07/19/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007820313 |
| Principal investigator 1 | Novo Nordisk AS | $10.56 | 07/19/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007820319 |
| Principal investigator 1 | Novo Nordisk AS | $10.56 | 07/19/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007820325 |
| Principal investigator 1 | Novo Nordisk AS | $10.56 | 07/19/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007820331 |
| Principal investigator 1 | Novo Nordisk AS | $10.56 | 07/19/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007820337 |
| Principal investigator 1 | PFIZER INC. | $1,485.00 | 07/13/2023 | Non-covered Recipient Entity University Clinical Research DeLand LLC | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1046346667 |
| Principal investigator 1 | ModernaTX, Inc. | $39,063.24 | 07/12/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults | No dispute reported | 06/30/2026 | 1041450799 |
| Principal investigator 1 | Janssen Research & Development, LLC | $260.00 | 07/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Randomized, Double-blind, Placebo-controlled Phase 1/2a Study for Safety and Immunogenicity Evaluations of various RSV.preF-based Vaccine Formulations in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 986140195 |
| Principal investigator 1 | ModernaTX, Inc. | $79,737.32 | 07/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults | No dispute reported | 06/30/2026 | 1041450783 |
| Principal investigator 1 | Janssen Research & Development, LLC | $120.00 | 07/04/2023 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 986108163 |
| Principal investigator 1 | Janssen Research & Development, LLC | $9,081.00 | 07/03/2023 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 986108165 |
| Principal investigator 1 | PFIZER INC. | $147.00 | 06/29/2023 | Non-covered Recipient Entity University Clinical Research DeLand LLC | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1046529551 |
| Principal investigator 1 | Novavax Inc | $2,565.00 | 06/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 | No dispute reported | 06/30/2026 | 1055262067 |
| Principal investigator 1 | Eli Lilly and Company | $416.40 | 06/27/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | RANDOMIZED PLACEBO-CONTROLLED PHASE 2 CLINICAL TRIAL TO EVALUATE LY3857210 FOR THE TREATMENT OF CHRONIC LOW BACK PAIN | No dispute reported | 06/30/2026 | 1038145303 |
| Principal investigator 1 | Eli Lilly and Company | $1,976.55 | 06/27/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A PARALLEL-GROUP SINGLE-DOSE PHASE 1 OPEN-LABEL STUDY TO INVESTIGATE THE PHARMACOKINETICS OF LY3437943 IN PARTICIPANTS WITH HEPATIC IMPAIRMENT COMPARED WITH HEALTHY PARTICIPANTS | No dispute reported | 06/30/2026 | 1038152869 |
| Principal investigator 1 | Janssen Research & Development, LLC | $150.00 | 06/27/2023 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants | No dispute reported | 06/30/2026 | 986108141 |
| Principal investigator 1 | Janssen Research & Development, LLC | $834.00 | 06/26/2023 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults | No dispute reported | 06/30/2026 | 986108149 |
| Principal investigator 1 | Bavarian Nordic A/S | $500.00 | 06/25/2023 | Non-covered Recipient Entity UNIV CLINICAL RESEARCH - DELAND LLC | A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 | No dispute reported | 06/30/2026 | 988694827 |
| Principal investigator 1 | Novo Nordisk AS | $1,484.14 | 06/23/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007822191 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,592.00 | 06/21/2023 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants | No dispute reported | 06/30/2026 | 986108139 |
| Principal investigator 1 | Novavax Inc | $2,219.00 | 06/20/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 | No dispute reported | 06/30/2026 | 1055266033 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $500.00 | 06/19/2023 | Non-covered Recipient Entity University Clinical Research Dela LLC | Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1035915305 |
| Principal investigator 1 | Janssen Research & Development, LLC | $78.00 | 06/16/2023 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 986108123 |
| Principal investigator 1 | Janssen Research & Development, LLC | $222.00 | 06/16/2023 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 986108125 |
| Principal investigator 1 | Janssen Research & Development, LLC | $500.00 | 06/16/2023 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 986108127 |
| Principal investigator 1 | PFIZER INC. | $1,500.00 | 06/16/2023 | Non-covered Recipient Entity University Clinical Research DeLand LLC | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1046502501 |
| Principal investigator 1 | American Regent | $2,335.00 | 06/14/2023 | Non-covered Recipient Entity University Clinical Rsearch - Deland, Llc | Heart_FID | No dispute reported | 06/30/2026 | 989343105 |
| Principal investigator 1 | ModernaTX, Inc. | $2,500.00 | 06/14/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1041436591 |
| Principal investigator 1 | ModernaTX, Inc. | $1,250.00 | 06/14/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1041436603 |
| Principal investigator 1 | ModernaTX, Inc. | $1,000.00 | 06/14/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1041436617 |
| Principal investigator 1 | Eli Lilly and Company | $1,356.00 | 06/13/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES GEORGIA LLC | A MULTIPLE-DOSE DOSE-ESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF LY3372993 IN PARTICIPANTS WITH ALZHEIMER'S DISEASE | No dispute reported | 06/30/2026 | 1038064865 |
| Principal investigator 1 | Eli Lilly and Company | $14,388.00 | 06/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A MASTER PROTOCOL FOR RANDOMIZED PLACEBO-CONTROLLED PHASE 2 CLINICAL TRIALS OF MULTIPLE INTERVENTIONS FOR THE TREATMENT OF CHRONIC PAIN | No dispute reported | 06/30/2026 | 1038155935 |
| Principal investigator 1 | Novavax Inc | $10,961.00 | 06/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 | No dispute reported | 06/30/2026 | 1055264007 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $2,717.40 | 06/13/2023 | Non-covered Recipient Entity University Clinical Research Dela LLC | Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1035915347 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 06/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041435171 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 06/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041435185 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 06/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041435197 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 06/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041435211 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 06/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041435223 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 06/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041435237 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 06/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041435253 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 06/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041435269 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 06/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041435283 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 06/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041435297 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 06/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041435309 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 06/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041435325 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 06/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041435339 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 06/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041435351 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 06/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041435363 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 06/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041435377 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 06/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041435393 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 06/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041435405 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 06/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041435419 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 06/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041435435 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 06/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041435449 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 06/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041435467 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 06/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041435481 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 06/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041435495 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 06/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041435511 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 06/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041435523 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 06/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041435537 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 06/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041435551 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 06/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041435565 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 06/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041435579 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 06/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041435593 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 06/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041435606 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 06/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041435621 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 06/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041435635 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 06/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041435651 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 06/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041435665 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 06/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041435679 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 06/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041435693 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 06/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041435707 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 06/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041435721 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 06/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041435735 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 06/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041435749 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 06/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041435763 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 06/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041435777 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 06/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041435791 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 06/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041435805 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 06/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041435819 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 06/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041435833 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 06/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041435847 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 06/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041435861 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 06/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041435875 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 06/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041435889 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 06/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041435903 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 06/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041435917 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 06/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041435931 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 06/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041435945 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 06/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041435961 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 06/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041435975 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 06/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041435991 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 06/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041436005 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 06/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041436019 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 06/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041436631 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 06/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041436645 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 06/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041436659 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 06/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041436675 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 06/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041436689 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 06/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041436703 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 06/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041436715 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 06/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041436729 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 06/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041436744 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 06/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041436757 |
| Principal investigator 1 | ModernaTX, Inc. | $155.50 | 06/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041436771 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 06/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041436785 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 06/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041436799 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 06/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041436813 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 06/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041436827 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 06/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041436841 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 06/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041436855 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 06/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041436869 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 06/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041436883 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 06/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041436899 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 06/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041436912 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 06/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041436925 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 06/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041436939 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 06/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041436955 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 06/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041436969 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 06/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041436983 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 06/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041436995 |
| Principal investigator 1 | Novavax Inc | $3,333.00 | 06/08/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 | No dispute reported | 06/30/2026 | 1055263095 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $13,450.00 | 06/07/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | A Randomized Double-Blind Parallel Group Multicenter 12 Week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants with Inadequately Controlled Asthma | No dispute reported | 06/30/2026 | 991128061 |
| Principal investigator 1 | ModernaTX, Inc. | $66.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041433695 |
| Principal investigator 1 | ModernaTX, Inc. | $66.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041433707 |
| Principal investigator 1 | ModernaTX, Inc. | $66.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041433737 |
| Principal investigator 1 | ModernaTX, Inc. | $66.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041433751 |
| Principal investigator 1 | ModernaTX, Inc. | $66.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041433765 |
| Principal investigator 1 | ModernaTX, Inc. | $66.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041433779 |
| Principal investigator 1 | ModernaTX, Inc. | $237.60 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041433793 |
| Principal investigator 1 | ModernaTX, Inc. | $118.80 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041433807 |
| Principal investigator 1 | ModernaTX, Inc. | $118.80 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041433821 |
| Principal investigator 1 | ModernaTX, Inc. | $118.80 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041433835 |
| Principal investigator 1 | ModernaTX, Inc. | $118.80 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041433849 |
| Principal investigator 1 | ModernaTX, Inc. | $217.80 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041433863 |
| Principal investigator 1 | ModernaTX, Inc. | $297.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041433877 |
| Principal investigator 1 | ModernaTX, Inc. | $297.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041433891 |
| Principal investigator 1 | ModernaTX, Inc. | $297.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041433905 |
| Principal investigator 1 | ModernaTX, Inc. | $594.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041433921 |
| Principal investigator 1 | ModernaTX, Inc. | $350.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041433935 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041433949 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041433963 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041433977 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041433993 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041434009 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041434023 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041434037 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041434051 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041434067 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041434081 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041434097 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041434111 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041434125 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041434139 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041434155 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041434169 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041434183 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041434197 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041434211 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041434225 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041434241 |
| Principal investigator 1 | ModernaTX, Inc. | $198.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041434253 |
| Principal investigator 1 | ModernaTX, Inc. | $198.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041434269 |
| Principal investigator 1 | ModernaTX, Inc. | $198.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041434283 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041434295 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041434307 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041434323 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041434337 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041434351 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041434365 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041434379 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041434393 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041434407 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041434423 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041434437 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041434453 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041434467 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041434483 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041434497 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041434511 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041434525 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041434537 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041434553 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041434567 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041434581 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041434595 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041434609 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041434623 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041434638 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041434655 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041434669 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041434683 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041434697 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041434711 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041434725 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041434739 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041434753 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041434769 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041434783 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041434801 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041434815 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041434829 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041434843 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041434857 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041434871 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041434885 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041434901 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041434915 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041434929 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041434945 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041434957 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041434971 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041434985 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041434999 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041435013 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041435029 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041435041 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041435055 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041435069 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041435083 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041435103 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041435115 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041435129 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041435143 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041435157 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041436033 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041436047 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041436059 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041436073 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041436087 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041436101 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041436117 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041436133 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041436145 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041436159 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041436175 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041436191 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041436205 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041436219 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041436231 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041436245 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041436257 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041436271 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041436285 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041436299 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041436313 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041436327 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041436345 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041436359 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041436373 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041436389 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041436401 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041436419 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041436433 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041436449 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041436461 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041436475 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041436489 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041436505 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041436519 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041436533 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041436547 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041436561 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041436575 |
| Principal investigator 1 | ModernaTX, Inc. | $108,040.78 | 06/07/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older | No dispute reported | 06/30/2026 | 1041450891 |
| Principal investigator 1 | ModernaTX, Inc. | $1,165.00 | 06/01/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older | No dispute reported | 06/30/2026 | 1041450749 |
| Principal investigator 1 | ModernaTX, Inc. | $10,000.00 | 06/01/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older | No dispute reported | 06/30/2026 | 1041450909 |
| Principal investigator 1 | ModernaTX, Inc. | $204.00 | 05/31/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age | No dispute reported | 06/30/2026 | 1042041495 |
| Principal investigator 1 | Janssen Research & Development, LLC | $11,676.00 | 05/30/2023 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 986108131 |
| Principal investigator 1 | Novavax Inc | $2,301.00 | 05/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 | No dispute reported | 06/30/2026 | 1055264005 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $13,450.00 | 05/26/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma | No dispute reported | 06/30/2026 | 991138405 |
| Principal investigator 1 | ModernaTX, Inc. | $8,500.00 | 05/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults | No dispute reported | 06/30/2026 | 1041450733 |
| Principal investigator 1 | Novo Nordisk AS | $3,388.90 | 05/26/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007822179 |
| Principal investigator 1 | Novo Nordisk AS | $500.00 | 05/26/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007822185 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $6,092.10 | 05/26/2023 | Non-covered Recipient Entity University Clinical Research Dela LLC | Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1035915277 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $1,798.30 | 05/26/2023 | Non-covered Recipient Entity University Clinical Research Dela LLC | Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1035915285 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $1,798.30 | 05/26/2023 | Non-covered Recipient Entity University Clinical Research Dela LLC | Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1035915295 |
| Principal investigator 1 | UCB SA | $12,400.00 | 05/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND REPEAT-DOSE (PART B, PARTICIPANT-, INVESTIGATOR-, AND SPONSOR-BLIND) STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY (PART B ONLY) OF UCB1381 IN HEALTHY STUDY PARTICIPANTS (PART A) AND IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (PART B) | No dispute reported | 06/30/2026 | 1059100891 |
| Principal investigator 1 | Eli Lilly and Company | $1,431.78 | 05/25/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A MASTER PROTOCOL FOR RANDOMIZED PLACEBO-CONTROLLED PHASE 2 CLINICAL TRIALS OF MULTIPLE INTERVENTIONS FOR THE TREATMENT OF CHRONIC PAIN | No dispute reported | 06/30/2026 | 1038151667 |
| Principal investigator 1 | Janssen Research & Development, LLC | $834.00 | 05/24/2023 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults | No dispute reported | 06/30/2026 | 986108147 |
| Principal investigator 1 | ModernaTX, Inc. | $1,500.00 | 05/24/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older | No dispute reported | 06/30/2026 | 1041448657 |
| Principal investigator 1 | ModernaTX, Inc. | $1,313.71 | 05/24/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older | No dispute reported | 06/30/2026 | 1041448673 |
| Principal investigator 1 | Novavax Inc | $11,647.00 | 05/24/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 | No dispute reported | 06/30/2026 | 1055264009 |
| Principal investigator 1 | Averitas Pharma Inc. | $925.00 | 05/19/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN | No dispute reported | 06/30/2026 | 1058764389 |
| Principal investigator 1 | ModernaTX, Inc. | $6,441.60 | 05/18/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041432331 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041429441 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041429455 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041429469 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041429487 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041429501 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041429513 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041429527 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041429540 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041429553 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041429569 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041429583 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041429597 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041429611 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041429625 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041429641 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041429655 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041429669 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041429683 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041429697 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041429709 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041429725 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041429740 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041429751 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041429761 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041429773 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041429785 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041429797 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041429807 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041430859 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041430873 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041430887 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041430901 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041430915 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041430929 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041430943 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041430957 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041430969 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041430987 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041431001 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041431015 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041431029 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041431043 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041431057 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041431071 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041431085 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041431101 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041431117 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041431133 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041431145 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041431161 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041431175 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041431189 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041431203 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041431217 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041431231 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041431245 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041431259 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041431275 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041431289 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041431302 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041431317 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041431331 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041431347 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041431361 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041431375 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041431389 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041431403 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041431419 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041431433 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041431447 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041431461 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041431475 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041431489 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041431505 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041431519 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041431533 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041431547 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041431561 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041431577 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041431591 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041431606 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041431618 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041431631 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041431643 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041431663 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041431677 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041431691 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041431705 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041431719 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041431733 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041431747 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041431761 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041431775 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041431789 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041431803 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041431817 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041431831 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041431845 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041431861 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041431875 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041431891 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041431905 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041431917 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041431935 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041431949 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041431967 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041431981 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041431997 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041432011 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041432025 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041432043 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041432059 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041432073 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041432089 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041432103 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041432117 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041432131 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041432145 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041432159 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041432173 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041432187 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041432201 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041432215 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041432229 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041432243 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041432258 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041432275 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041432289 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041432345 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041432361 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041432375 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041432389 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041432403 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041432417 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041432431 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041432447 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041432463 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041432477 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041432491 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041432505 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041432519 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041432533 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041432547 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041432561 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041432576 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041432591 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041432607 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041432621 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041432635 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041432649 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041432663 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041432679 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041432693 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041432707 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041432721 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041432735 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041432749 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041432765 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041432779 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041432793 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041432807 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041432823 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041432837 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041432851 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041432865 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041432879 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041432893 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041432909 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041432925 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041432939 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041432953 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041432967 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041432981 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041432995 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041433009 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041433025 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041433039 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041433053 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041433067 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041433079 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041433095 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041433109 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041433123 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041433137 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041433153 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041433167 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041433181 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041433195 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041433209 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041433223 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041433237 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041433251 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041433265 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041433277 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041433291 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041433307 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041433321 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041433335 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041433349 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041433365 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041433379 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041433393 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041433409 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041433423 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041433437 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041433451 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041433467 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041433481 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041433495 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041433509 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041433523 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041433539 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041433553 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041433567 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041433581 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041433593 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041433609 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041433627 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041433641 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041433655 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041433669 |
| Principal investigator 1 | ModernaTX, Inc. | $13.20 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041433683 |
| Principal investigator 1 | ModernaTX, Inc. | $1,000.00 | 05/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older | No dispute reported | 06/30/2026 | 1041448643 |
| Principal investigator 1 | Novavax Inc | $5,634.00 | 05/16/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 | No dispute reported | 06/30/2026 | 1055259107 |
| Principal investigator 1 | Novo Nordisk AS | $23.13 | 05/16/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1006862359 |
| Principal investigator 1 | Novo Nordisk AS | $23.13 | 05/16/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1006862371 |
| Principal investigator 1 | Novo Nordisk AS | $23.13 | 05/16/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1006862381 |
| Principal investigator 1 | Novo Nordisk AS | $23.13 | 05/16/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1008472751 |
| Principal investigator 1 | Novo Nordisk AS | $23.13 | 05/16/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1008472767 |
| Principal investigator 1 | Novo Nordisk AS | $23.13 | 05/16/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1008472781 |
| Principal investigator 1 | Novo Nordisk AS | $600.00 | 05/12/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9535-4984 | No dispute reported | 06/30/2026 | 1008267717 |
| Principal investigator 1 | Chiesi USA, Inc. | $500.00 | 05/11/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) | No dispute reported | 06/30/2026 | 1051595043 |
| Principal investigator 1 | Novavax Inc | $7,875.00 | 05/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 | No dispute reported | 06/30/2026 | 1055263093 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,125.00 | 05/05/2023 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants | No dispute reported | 06/30/2026 | 986108135 |
| Principal investigator 1 | Chiesi USA, Inc. | $6,500.00 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) | No dispute reported | 06/30/2026 | 1051594329 |
| Principal investigator 1 | Chiesi USA, Inc. | $3,807.00 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) | No dispute reported | 06/30/2026 | 1051594331 |
| Principal investigator 1 | Chiesi USA, Inc. | $2,586.00 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) | No dispute reported | 06/30/2026 | 1051594333 |
| Principal investigator 1 | Chiesi USA, Inc. | $1,106.00 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) | No dispute reported | 06/30/2026 | 1051594337 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041428785 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041428799 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041428815 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041428829 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041428845 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041428863 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041428877 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041428891 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041428905 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041428919 |
| Principal investigator 1 | ModernaTX, Inc. | $155.50 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041428933 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041428949 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041428963 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041428979 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041428993 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041429009 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041429023 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041429037 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041429053 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041429069 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041429081 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041429095 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041429111 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041429125 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041429137 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041429149 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041429197 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041429211 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041429225 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041429239 |
| Principal investigator 1 | ModernaTX, Inc. | $155.50 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041429253 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041429267 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041429281 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041429297 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041429311 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041429325 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041429339 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041429353 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041429371 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041429385 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041429399 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041429413 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041429427 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041429821 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041429835 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041429849 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041429861 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041429873 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041429887 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041429901 |
| Principal investigator 1 | ModernaTX, Inc. | $155.50 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041429913 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041429927 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041429943 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041429957 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041429971 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041429987 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041429999 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041430015 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041430027 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041430043 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041430073 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041430087 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041430101 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041430117 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041430131 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041430145 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041430163 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041430189 |
| Principal investigator 1 | ModernaTX, Inc. | $155.50 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041430203 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041430219 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041430235 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041430249 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041430263 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041430283 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041430297 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041430311 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041430327 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041430341 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041430355 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041430369 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041430383 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041430399 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041430415 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041430429 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041430442 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041430455 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041430470 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041430487 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041430501 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041430515 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041430529 |
| Principal investigator 1 | ModernaTX, Inc. | $155.50 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041430543 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041430557 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041430571 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041430585 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041430604 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041430617 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041430632 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041430647 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041430661 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041430675 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041430691 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041430705 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041430719 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041430733 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041430747 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041430761 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041430775 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041430789 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041430803 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041430817 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041430831 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 05/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041430845 |
| Principal investigator 1 | Novavax Inc | $17,817.00 | 04/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 | No dispute reported | 06/30/2026 | 1055261069 |
| Principal investigator 1 | Novo Nordisk AS | $3,113.85 | 04/26/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9535-4984 | No dispute reported | 06/30/2026 | 1008267701 |
| Principal investigator 1 | Janssen Pharmaceuticals, Inc | $896.00 | 04/21/2023 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 986093517 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,846.00 | 04/21/2023 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 986108129 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,173.00 | 04/21/2023 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants | No dispute reported | 06/30/2026 | 986108133 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,004.00 | 04/21/2023 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults | No dispute reported | 06/30/2026 | 986108145 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,500.00 | 04/20/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Randomized, Double-blind Phase 3 Study to Assess the Immunogenicity and Safety of an Ad26.RSV.PreF-based Regimen at the End of Shelf-life in Adults Aged 60 to Less Than 65Years | No dispute reported | 06/30/2026 | 986140183 |
| Principal investigator 1 | ModernaTX, Inc. | $10,000.00 | 04/20/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1042041389 |
| Principal investigator 1 | Novavax Inc | $885.00 | 04/20/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) | No dispute reported | 06/30/2026 | 1055259105 |
| Principal investigator 1 | Eli Lilly and Company | $37,587.00 | 04/18/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | RANDOMIZED PLACEBO CONTROLLED PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN | No dispute reported | 06/30/2026 | 1038149959 |
| Principal investigator 1 | Novavax Inc | $354.00 | 04/18/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 | No dispute reported | 06/30/2026 | 1055263089 |
| Principal investigator 1 | Novavax Inc | $5,256.00 | 04/18/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) | No dispute reported | 06/30/2026 | 1055265017 |
| Principal investigator 1 | Janssen Research & Development, LLC | $250.00 | 04/17/2023 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults | No dispute reported | 06/30/2026 | 986108143 |
| Principal investigator 1 | ModernaTX, Inc. | $150.00 | 04/14/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES - ST. PETERSBURG- LARGO | A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 | No dispute reported | 06/30/2026 | 1041511767 |
| Principal investigator 1 | Novavax Inc | $4,779.00 | 04/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 | No dispute reported | 06/30/2026 | 1055261071 |
| Principal investigator 1 | Janssen Research & Development, LLC | $400.00 | 04/12/2023 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants | No dispute reported | 06/30/2026 | 986108137 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $128,584.77 | 04/10/2023 | Non-covered Recipient Entity University Clinical Research Dela LLC | Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1035915337 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $6,642.65 | 04/07/2023 | Non-covered Recipient Entity University Clinical Research Dela LLC | Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1035915325 |
| Principal investigator 1 | Eli Lilly and Company | $102.20 | 04/05/2023 | Non-covered Recipient Entity ACHIEVE CLINICAL RESEARCH LLC | RANDOMIZED PLACEBO CONTROLLED PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN | No dispute reported | 06/30/2026 | 1038064885 |
| Principal investigator 1 | ModernaTX, Inc. | $100.00 | 04/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041448435 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 04/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1042041091 |
| Principal investigator 1 | ModernaTX, Inc. | $1,285.35 | 04/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1042041097 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 04/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1042041103 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 04/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1042041109 |
| Principal investigator 1 | ModernaTX, Inc. | $1,285.35 | 04/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1042041117 |
| Principal investigator 1 | ModernaTX, Inc. | $1,285.35 | 04/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1042041121 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 04/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1042041127 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 04/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1042041133 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 04/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1042041139 |
| Principal investigator 1 | ModernaTX, Inc. | $1,285.35 | 04/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1042041145 |
| Principal investigator 1 | ModernaTX, Inc. | $1,285.35 | 04/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1042041151 |
| Principal investigator 1 | ModernaTX, Inc. | $1,285.35 | 04/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1042041157 |
| Principal investigator 1 | ModernaTX, Inc. | $1,285.35 | 04/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1042041163 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 04/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1042041169 |
| Principal investigator 1 | ModernaTX, Inc. | $1,285.35 | 04/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1042041175 |
| Principal investigator 1 | ModernaTX, Inc. | $155.50 | 04/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1042041181 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 04/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1042041187 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 04/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1042041193 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 04/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1042041199 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 04/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1042041205 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 04/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1042041211 |
| Principal investigator 1 | ModernaTX, Inc. | $1,285.35 | 04/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1042041217 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 04/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1042041223 |
| Principal investigator 1 | ModernaTX, Inc. | $1,285.35 | 04/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1042041229 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 04/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1042041235 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 04/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1042041241 |
| Principal investigator 1 | ModernaTX, Inc. | $155.50 | 04/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1042041247 |
| Principal investigator 1 | ModernaTX, Inc. | $1,285.35 | 04/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1042041253 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 04/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1042041259 |
| Principal investigator 1 | ModernaTX, Inc. | $155.50 | 04/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1042041267 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 04/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1042041273 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 04/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1042041279 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 04/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1042041285 |
| Principal investigator 1 | ModernaTX, Inc. | $1,285.35 | 04/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1042041291 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 04/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1042041297 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 04/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1042041303 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 04/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1042041309 |
| Principal investigator 1 | ModernaTX, Inc. | $1,285.35 | 04/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1042041315 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 04/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1042041321 |
| Principal investigator 1 | ModernaTX, Inc. | $155.50 | 04/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1042041327 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 04/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1042041335 |
| Principal investigator 1 | ModernaTX, Inc. | $1,285.35 | 04/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1042041341 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 04/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1042041345 |
| Principal investigator 1 | ModernaTX, Inc. | $1,285.35 | 04/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1042041353 |
| Principal investigator 1 | ModernaTX, Inc. | $1,285.35 | 04/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1042041359 |
| Principal investigator 1 | ModernaTX, Inc. | $1,285.35 | 04/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1042041365 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 04/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1042041371 |
| Principal investigator 1 | ModernaTX, Inc. | $1,285.35 | 04/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1042041377 |
| Principal investigator 1 | ModernaTX, Inc. | $1,285.35 | 04/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1042041383 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 04/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1042041395 |
| Principal investigator 1 | ModernaTX, Inc. | $1,285.35 | 04/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1042041403 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 04/05/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1042041409 |
| Principal investigator 1 | Novavax Inc | $6,018.00 | 04/04/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 | No dispute reported | 06/30/2026 | 1055260071 |
| Principal investigator 1 | ModernaTX, Inc. | $66.00 | 03/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041428045 |
| Principal investigator 1 | ModernaTX, Inc. | $297.00 | 03/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041428239 |
| Principal investigator 1 | ModernaTX, Inc. | $2,317.23 | 03/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041428295 |
| Principal investigator 1 | ModernaTX, Inc. | $66.00 | 03/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041428383 |
| Principal investigator 1 | ModernaTX, Inc. | $66.00 | 03/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041428399 |
| Principal investigator 1 | ModernaTX, Inc. | $297.00 | 03/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041428727 |
| Principal investigator 1 | ModernaTX, Inc. | $1,500.00 | 03/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041428743 |
| Principal investigator 1 | Averitas Pharma Inc. | $256.00 | 03/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN | No dispute reported | 06/30/2026 | 1058764385 |
| Principal investigator 1 | Averitas Pharma Inc. | $150.00 | 03/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN | No dispute reported | 06/30/2026 | 1058764387 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 03/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041428005 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 03/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041428019 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 03/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041428033 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 03/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041428059 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 03/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041428077 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 03/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041428091 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 03/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041428105 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 03/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041428117 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 03/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041428125 |
| Principal investigator 1 | ModernaTX, Inc. | $198.00 | 03/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041428139 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 03/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041428153 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 03/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041428167 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 03/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041428183 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 03/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041428197 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 03/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041428211 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 03/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041428225 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 03/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041428253 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 03/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041428267 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 03/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041428281 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 03/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041428313 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 03/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041428327 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 03/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041428341 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 03/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041428353 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 03/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041428367 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 03/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041428425 |
| Principal investigator 1 | ModernaTX, Inc. | $66.00 | 03/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041428439 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 03/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041428453 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 03/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041428469 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 03/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041428511 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 03/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041428525 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 03/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041428539 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 03/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041428555 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 03/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041428571 |
| Principal investigator 1 | ModernaTX, Inc. | $66.00 | 03/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041428615 |
| Principal investigator 1 | ModernaTX, Inc. | $500.00 | 03/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041428629 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 03/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041428643 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 03/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041428655 |
| Principal investigator 1 | ModernaTX, Inc. | $66.00 | 03/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041428671 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 03/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041428685 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 03/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041428699 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 03/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041428713 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 03/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041428755 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 03/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041428769 |
| Principal investigator 1 | Novavax Inc | $354.00 | 03/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 | No dispute reported | 06/30/2026 | 1055260069 |
| Principal investigator 1 | Novavax Inc | $1,133.00 | 03/29/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) | No dispute reported | 06/30/2026 | 1055263091 |
| Principal investigator 1 | Novo Nordisk AS | $18.25 | 03/29/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007417595 |
| Principal investigator 1 | Novo Nordisk AS | $18.25 | 03/29/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007417603 |
| Principal investigator 1 | Novo Nordisk AS | $18.25 | 03/29/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007417613 |
| Principal investigator 1 | Novo Nordisk AS | $18.25 | 03/29/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007417621 |
| Principal investigator 1 | Novo Nordisk AS | $18.25 | 03/29/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007417629 |
| Principal investigator 1 | Novo Nordisk AS | $18.25 | 03/29/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007417637 |
| Principal investigator 1 | Novo Nordisk AS | $18.25 | 03/29/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007417645 |
| Principal investigator 1 | Novo Nordisk AS | $18.25 | 03/29/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007417653 |
| Principal investigator 1 | Novo Nordisk AS | $18.25 | 03/29/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007417661 |
| Principal investigator 1 | Novo Nordisk AS | $18.25 | 03/29/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007544603 |
| Principal investigator 1 | Novo Nordisk AS | $18.25 | 03/29/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007544617 |
| Principal investigator 1 | Novo Nordisk AS | $18.25 | 03/29/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007544631 |
| Principal investigator 1 | Novo Nordisk AS | $18.25 | 03/29/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007544645 |
| Principal investigator 1 | Novo Nordisk AS | $18.25 | 03/29/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007544659 |
| Principal investigator 1 | Novo Nordisk AS | $18.25 | 03/29/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007544675 |
| Principal investigator 1 | Novo Nordisk AS | $18.25 | 03/29/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007544689 |
| Principal investigator 1 | Novo Nordisk AS | $18.25 | 03/29/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007544701 |
| Principal investigator 1 | Novo Nordisk AS | $18.25 | 03/29/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007544715 |
| Principal investigator 1 | Novo Nordisk AS | $18.25 | 03/29/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007673715 |
| Principal investigator 1 | Novo Nordisk AS | $18.25 | 03/29/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007673733 |
| Principal investigator 1 | Novo Nordisk AS | $18.25 | 03/29/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007673745 |
| Principal investigator 1 | Novo Nordisk AS | $18.25 | 03/29/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007673757 |
| Principal investigator 1 | Novo Nordisk AS | $18.25 | 03/29/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007673771 |
| Principal investigator 1 | Novo Nordisk AS | $18.25 | 03/29/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007673783 |
| Principal investigator 1 | Novo Nordisk AS | $18.25 | 03/29/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007673795 |
| Principal investigator 1 | Novo Nordisk AS | $18.25 | 03/29/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007797145 |
| Principal investigator 1 | Novo Nordisk AS | $18.25 | 03/29/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007797153 |
| Principal investigator 1 | Novo Nordisk AS | $18.25 | 03/29/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007797163 |
| Principal investigator 1 | Novo Nordisk AS | $18.25 | 03/29/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007797171 |
| Principal investigator 1 | Novo Nordisk AS | $18.25 | 03/29/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007797179 |
| Principal investigator 1 | Novo Nordisk AS | $18.25 | 03/29/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007797187 |
| Principal investigator 1 | Novo Nordisk AS | $18.25 | 03/29/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007797197 |
| Principal investigator 1 | Novo Nordisk AS | $18.25 | 03/29/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007797205 |
| Principal investigator 1 | Novo Nordisk AS | $18.25 | 03/29/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007797213 |
| Principal investigator 1 | Novo Nordisk AS | $18.25 | 03/29/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007797221 |
| Principal investigator 1 | Novo Nordisk AS | $18.25 | 03/29/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007820343 |
| Principal investigator 1 | Novo Nordisk AS | $18.25 | 03/29/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007820351 |
| Principal investigator 1 | Novo Nordisk AS | $18.25 | 03/29/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007927025 |
| Principal investigator 1 | Novo Nordisk AS | $18.25 | 03/29/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1008130465 |
| Principal investigator 1 | Novo Nordisk AS | $18.25 | 03/29/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1008130483 |
| Principal investigator 1 | Novo Nordisk AS | $18.25 | 03/29/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1008130497 |
| Principal investigator 1 | Novo Nordisk AS | $18.25 | 03/29/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1008130511 |
| Principal investigator 1 | Novo Nordisk AS | $18.25 | 03/29/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1008130525 |
| Principal investigator 1 | Novo Nordisk AS | $18.25 | 03/29/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1008130541 |
| Principal investigator 1 | Novo Nordisk AS | $18.25 | 03/29/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1008130555 |
| Principal investigator 1 | Novo Nordisk AS | $18.25 | 03/29/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1008130569 |
| Principal investigator 1 | Novo Nordisk AS | $18.25 | 03/29/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1008130585 |
| Principal investigator 1 | Novo Nordisk AS | $18.25 | 03/29/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1008130601 |
| Principal investigator 1 | Novo Nordisk AS | $18.25 | 03/29/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1008130617 |
| Principal investigator 1 | Novo Nordisk AS | $18.25 | 03/29/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1008472881 |
| Principal investigator 1 | Novo Nordisk AS | $18.25 | 03/29/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1008472891 |
| Principal investigator 1 | Novo Nordisk AS | $18.25 | 03/29/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1008472903 |
| Principal investigator 1 | Novo Nordisk AS | $18.25 | 03/29/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1008472911 |
| Principal investigator 1 | Novo Nordisk AS | $18.25 | 03/29/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1008472925 |
| Principal investigator 1 | Novo Nordisk AS | $18.25 | 03/29/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1008472939 |
| Principal investigator 1 | Novo Nordisk AS | $18.25 | 03/29/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1008472955 |
| Principal investigator 1 | Novo Nordisk AS | $18.25 | 03/29/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1008472973 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $71,325.28 | 03/29/2023 | Non-covered Recipient Entity University Clinical Research Dela LLC | Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1035915265 |
| Principal investigator 1 | Janssen Pharmaceuticals, Inc | $3,043.00 | 03/27/2023 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 986093513 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,194.34 | 03/24/2023 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 986108083 |
| Principal investigator 1 | Novavax Inc | $1,133.00 | 03/24/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) | No dispute reported | 06/30/2026 | 1055265015 |
| Principal investigator 1 | Novavax Inc | $5,841.00 | 03/24/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 | No dispute reported | 06/30/2026 | 1055266029 |
| Principal investigator 1 | Novo Nordisk AS | $3,986.77 | 03/24/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1008104415 |
| Principal investigator 1 | Novo Nordisk AS | $11,236.65 | 03/24/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9535-4984 | No dispute reported | 06/30/2026 | 1008267687 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,331.00 | 03/23/2023 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 986108089 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 03/23/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041426573 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 03/23/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041426587 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 03/23/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041426601 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 03/23/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041426615 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 03/23/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041426629 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 03/23/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041426643 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 03/23/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041426657 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 03/23/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041427193 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 03/23/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041428411 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 03/23/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041428483 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 03/23/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041428497 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 03/23/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041428585 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 03/23/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041428599 |
| Principal investigator 1 | Janssen Pharmaceuticals, Inc | $4,424.00 | 03/22/2023 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 986093515 |
| Principal investigator 1 | Novavax Inc | $6,195.00 | 03/21/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 | No dispute reported | 06/30/2026 | 1055259103 |
| Principal investigator 1 | Novavax Inc | $832.00 | 03/21/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) | No dispute reported | 06/30/2026 | 1055264001 |
| Principal investigator 1 | Janssen Research & Development, LLC | $387.00 | 03/20/2023 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants | No dispute reported | 06/30/2026 | 986108103 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,475.00 | 03/20/2023 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults | No dispute reported | 06/30/2026 | 986108109 |
| Principal investigator 1 | Janssen Research & Development, LLC | $118.00 | 03/17/2023 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 986108087 |
| Principal investigator 1 | Janssen Research & Development, LLC | $31,652.00 | 03/17/2023 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants | No dispute reported | 06/30/2026 | 986108105 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,198.81 | 03/16/2023 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 986108081 |
| Principal investigator 1 | Janssen Research & Development, LLC | $25.00 | 03/16/2023 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 986108085 |
| Principal investigator 1 | Janssen Research & Development, LLC | $500.00 | 03/16/2023 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 986108091 |
| Principal investigator 1 | Novavax Inc | $3,540.00 | 03/16/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) | No dispute reported | 06/30/2026 | 1055260067 |
| Principal investigator 1 | Novavax Inc | $6,688.00 | 03/15/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) | No dispute reported | 06/30/2026 | 1055261073 |
| Principal investigator 1 | Novavax Inc | $5,841.00 | 03/15/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 | No dispute reported | 06/30/2026 | 1055266031 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $1,000.00 | 03/14/2023 | Non-covered Recipient Entity University Clinical Research Dela LLC | Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1035915155 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $500.00 | 03/14/2023 | Non-covered Recipient Entity University Clinical Research Dela LLC | Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1035915165 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $750.00 | 03/14/2023 | Non-covered Recipient Entity University Clinical Research Dela LLC | Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1035915177 |
| Principal investigator 1 | ModernaTX, Inc. | $1,452.13 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041425059 |
| Principal investigator 1 | ModernaTX, Inc. | $1,925.52 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041425071 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041425085 |
| Principal investigator 1 | ModernaTX, Inc. | $155.50 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041425099 |
| Principal investigator 1 | ModernaTX, Inc. | $155.50 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041425115 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041425133 |
| Principal investigator 1 | ModernaTX, Inc. | $1,285.35 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041425147 |
| Principal investigator 1 | ModernaTX, Inc. | $1,452.13 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041425161 |
| Principal investigator 1 | ModernaTX, Inc. | $3,254.39 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041425175 |
| Principal investigator 1 | ModernaTX, Inc. | $1,452.13 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041425191 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041425205 |
| Principal investigator 1 | ModernaTX, Inc. | $1,285.35 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041425219 |
| Principal investigator 1 | ModernaTX, Inc. | $1,925.52 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041425231 |
| Principal investigator 1 | ModernaTX, Inc. | $1,285.35 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041425244 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041425257 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041425273 |
| Principal investigator 1 | ModernaTX, Inc. | $1,925.52 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041425287 |
| Principal investigator 1 | ModernaTX, Inc. | $1,285.35 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041425301 |
| Principal investigator 1 | ModernaTX, Inc. | $2,201.40 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041425313 |
| Principal investigator 1 | ModernaTX, Inc. | $1,452.13 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041425327 |
| Principal investigator 1 | ModernaTX, Inc. | $1,925.52 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041425345 |
| Principal investigator 1 | ModernaTX, Inc. | $1,452.13 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041425359 |
| Principal investigator 1 | ModernaTX, Inc. | $1,452.13 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041425373 |
| Principal investigator 1 | ModernaTX, Inc. | $155.50 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041425387 |
| Principal investigator 1 | ModernaTX, Inc. | $2,201.40 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041425401 |
| Principal investigator 1 | ModernaTX, Inc. | $2,201.40 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041425415 |
| Principal investigator 1 | ModernaTX, Inc. | $2,201.40 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041425429 |
| Principal investigator 1 | ModernaTX, Inc. | $1,285.35 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041425443 |
| Principal investigator 1 | ModernaTX, Inc. | $155.50 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041425457 |
| Principal investigator 1 | ModernaTX, Inc. | $2,201.40 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041425471 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041425485 |
| Principal investigator 1 | ModernaTX, Inc. | $1,925.52 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041425499 |
| Principal investigator 1 | ModernaTX, Inc. | $2,201.40 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041425513 |
| Principal investigator 1 | ModernaTX, Inc. | $1,925.52 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041425529 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041425545 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041425559 |
| Principal investigator 1 | ModernaTX, Inc. | $1,925.52 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041425573 |
| Principal investigator 1 | ModernaTX, Inc. | $1,925.52 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041425589 |
| Principal investigator 1 | ModernaTX, Inc. | $1,925.52 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041425603 |
| Principal investigator 1 | ModernaTX, Inc. | $1,925.52 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041425617 |
| Principal investigator 1 | ModernaTX, Inc. | $600.00 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041425631 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041425645 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041425659 |
| Principal investigator 1 | ModernaTX, Inc. | $1,285.35 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041425673 |
| Principal investigator 1 | ModernaTX, Inc. | $1,452.13 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041425687 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041425701 |
| Principal investigator 1 | ModernaTX, Inc. | $1,452.13 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041425715 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041425729 |
| Principal investigator 1 | ModernaTX, Inc. | $2,201.40 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041425745 |
| Principal investigator 1 | ModernaTX, Inc. | $2,201.40 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041425757 |
| Principal investigator 1 | ModernaTX, Inc. | $2,201.40 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041425772 |
| Principal investigator 1 | ModernaTX, Inc. | $2,201.40 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041425787 |
| Principal investigator 1 | ModernaTX, Inc. | $1,925.52 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041425801 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041425817 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041425833 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041425845 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041425859 |
| Principal investigator 1 | ModernaTX, Inc. | $2,201.40 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041425875 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041425889 |
| Principal investigator 1 | ModernaTX, Inc. | $1,452.13 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041425903 |
| Principal investigator 1 | ModernaTX, Inc. | $1,452.13 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041425917 |
| Principal investigator 1 | ModernaTX, Inc. | $1,452.13 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041425931 |
| Principal investigator 1 | ModernaTX, Inc. | $1,925.52 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041425945 |
| Principal investigator 1 | ModernaTX, Inc. | $1,925.52 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041425959 |
| Principal investigator 1 | ModernaTX, Inc. | $155.50 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041425973 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041425987 |
| Principal investigator 1 | ModernaTX, Inc. | $1,285.35 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041426001 |
| Principal investigator 1 | ModernaTX, Inc. | $1,925.52 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041426015 |
| Principal investigator 1 | ModernaTX, Inc. | $1,285.35 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041426029 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041426044 |
| Principal investigator 1 | ModernaTX, Inc. | $1,925.52 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041426061 |
| Principal investigator 1 | ModernaTX, Inc. | $1,285.35 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041426075 |
| Principal investigator 1 | ModernaTX, Inc. | $155.50 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041426089 |
| Principal investigator 1 | ModernaTX, Inc. | $1,452.13 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041426105 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041426119 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041426133 |
| Principal investigator 1 | ModernaTX, Inc. | $2,201.40 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041426147 |
| Principal investigator 1 | ModernaTX, Inc. | $1,452.13 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041426161 |
| Principal investigator 1 | ModernaTX, Inc. | $2,201.40 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041426175 |
| Principal investigator 1 | ModernaTX, Inc. | $1,925.52 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041426189 |
| Principal investigator 1 | ModernaTX, Inc. | $2,201.40 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041426203 |
| Principal investigator 1 | ModernaTX, Inc. | $1,925.52 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041426217 |
| Principal investigator 1 | ModernaTX, Inc. | $1,925.52 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041426231 |
| Principal investigator 1 | ModernaTX, Inc. | $1,925.52 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041426245 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041426259 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041426273 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041426289 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041426303 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041426317 |
| Principal investigator 1 | ModernaTX, Inc. | $1,452.13 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041426331 |
| Principal investigator 1 | ModernaTX, Inc. | $1,452.13 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041426345 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041426361 |
| Principal investigator 1 | ModernaTX, Inc. | $155.50 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041426375 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041426389 |
| Principal investigator 1 | ModernaTX, Inc. | $155.50 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041426403 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041426417 |
| Principal investigator 1 | ModernaTX, Inc. | $1,452.13 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041426431 |
| Principal investigator 1 | ModernaTX, Inc. | $1,925.52 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041426445 |
| Principal investigator 1 | ModernaTX, Inc. | $2,201.40 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041426461 |
| Principal investigator 1 | ModernaTX, Inc. | $1,452.13 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041426471 |
| Principal investigator 1 | ModernaTX, Inc. | $1,452.13 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041426484 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041426499 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041426515 |
| Principal investigator 1 | ModernaTX, Inc. | $1,925.52 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041426531 |
| Principal investigator 1 | ModernaTX, Inc. | $1,452.13 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041426545 |
| Principal investigator 1 | ModernaTX, Inc. | $1,452.13 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041426559 |
| Principal investigator 1 | ModernaTX, Inc. | $1,452.13 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041426671 |
| Principal investigator 1 | ModernaTX, Inc. | $155.50 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041426687 |
| Principal investigator 1 | ModernaTX, Inc. | $1,285.35 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041426699 |
| Principal investigator 1 | ModernaTX, Inc. | $1,285.35 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041426713 |
| Principal investigator 1 | ModernaTX, Inc. | $155.50 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041426727 |
| Principal investigator 1 | ModernaTX, Inc. | $1,925.52 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041426741 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041426759 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041426775 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041426789 |
| Principal investigator 1 | ModernaTX, Inc. | $1,452.13 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041426801 |
| Principal investigator 1 | ModernaTX, Inc. | $155.50 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041426817 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041426831 |
| Principal investigator 1 | ModernaTX, Inc. | $1,925.52 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041426845 |
| Principal investigator 1 | ModernaTX, Inc. | $1,285.35 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041426859 |
| Principal investigator 1 | ModernaTX, Inc. | $1,925.52 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041426873 |
| Principal investigator 1 | ModernaTX, Inc. | $2,201.40 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041426887 |
| Principal investigator 1 | ModernaTX, Inc. | $1,285.35 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041426905 |
| Principal investigator 1 | ModernaTX, Inc. | $2,201.40 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041426921 |
| Principal investigator 1 | ModernaTX, Inc. | $1,925.52 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041426935 |
| Principal investigator 1 | ModernaTX, Inc. | $1,285.35 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041426949 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041426963 |
| Principal investigator 1 | ModernaTX, Inc. | $1,925.52 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041426977 |
| Principal investigator 1 | ModernaTX, Inc. | $1,452.13 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041426991 |
| Principal investigator 1 | ModernaTX, Inc. | $155.50 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041427005 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041427019 |
| Principal investigator 1 | ModernaTX, Inc. | $1,452.13 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041427033 |
| Principal investigator 1 | ModernaTX, Inc. | $1,285.35 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041427047 |
| Principal investigator 1 | ModernaTX, Inc. | $1,452.13 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041427064 |
| Principal investigator 1 | ModernaTX, Inc. | $1,925.52 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041427079 |
| Principal investigator 1 | ModernaTX, Inc. | $2,201.40 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041427093 |
| Principal investigator 1 | ModernaTX, Inc. | $2,201.40 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041427107 |
| Principal investigator 1 | ModernaTX, Inc. | $1,925.52 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041427121 |
| Principal investigator 1 | ModernaTX, Inc. | $1,285.35 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041427137 |
| Principal investigator 1 | ModernaTX, Inc. | $1,452.13 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041427151 |
| Principal investigator 1 | ModernaTX, Inc. | $155.50 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041427165 |
| Principal investigator 1 | ModernaTX, Inc. | $1,285.35 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041427179 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041427207 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041427221 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041427237 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041427251 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041427265 |
| Principal investigator 1 | ModernaTX, Inc. | $155.50 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041427279 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041427293 |
| Principal investigator 1 | ModernaTX, Inc. | $1,925.52 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041427307 |
| Principal investigator 1 | ModernaTX, Inc. | $2,201.40 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041427321 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041427335 |
| Principal investigator 1 | ModernaTX, Inc. | $155.50 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041427349 |
| Principal investigator 1 | ModernaTX, Inc. | $1,452.13 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041427363 |
| Principal investigator 1 | ModernaTX, Inc. | $2,201.40 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041427377 |
| Principal investigator 1 | ModernaTX, Inc. | $2,201.40 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041427391 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041427405 |
| Principal investigator 1 | ModernaTX, Inc. | $1,452.13 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041427419 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041427433 |
| Principal investigator 1 | ModernaTX, Inc. | $1,285.35 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041427445 |
| Principal investigator 1 | ModernaTX, Inc. | $1,285.35 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041427459 |
| Principal investigator 1 | ModernaTX, Inc. | $1,452.13 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041427473 |
| Principal investigator 1 | ModernaTX, Inc. | $1,452.13 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041427487 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041427501 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041427515 |
| Principal investigator 1 | ModernaTX, Inc. | $1,452.13 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041427531 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041427543 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041427560 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041427575 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041427589 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041427605 |
| Principal investigator 1 | ModernaTX, Inc. | $2,201.40 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041427619 |
| Principal investigator 1 | ModernaTX, Inc. | $1,925.52 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041427631 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041427645 |
| Principal investigator 1 | ModernaTX, Inc. | $2,201.40 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041427661 |
| Principal investigator 1 | ModernaTX, Inc. | $1,285.35 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041427675 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041427693 |
| Principal investigator 1 | ModernaTX, Inc. | $1,925.52 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041427707 |
| Principal investigator 1 | ModernaTX, Inc. | $2,201.40 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041427721 |
| Principal investigator 1 | ModernaTX, Inc. | $155.50 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041427737 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041427749 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041427763 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041427775 |
| Principal investigator 1 | ModernaTX, Inc. | $1,925.52 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041427791 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041427805 |
| Principal investigator 1 | ModernaTX, Inc. | $1,452.13 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041427819 |
| Principal investigator 1 | ModernaTX, Inc. | $1,452.13 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041427833 |
| Principal investigator 1 | ModernaTX, Inc. | $1,452.13 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041427847 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041427861 |
| Principal investigator 1 | ModernaTX, Inc. | $1,285.35 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041427873 |
| Principal investigator 1 | ModernaTX, Inc. | $1,452.13 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041427887 |
| Principal investigator 1 | ModernaTX, Inc. | $1,285.35 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041427901 |
| Principal investigator 1 | ModernaTX, Inc. | $1,925.52 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041427919 |
| Principal investigator 1 | ModernaTX, Inc. | $1,925.52 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041427935 |
| Principal investigator 1 | ModernaTX, Inc. | $2,201.40 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041427949 |
| Principal investigator 1 | ModernaTX, Inc. | $155.50 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041427963 |
| Principal investigator 1 | ModernaTX, Inc. | $155.50 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041427977 |
| Principal investigator 1 | ModernaTX, Inc. | $1,285.35 | 03/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041427989 |
| Principal investigator 1 | PFIZER INC. | $8,534.16 | 03/11/2023 | Non-covered Recipient Entity University Clinical Research DeLand LLC | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1046546487 |
| Principal investigator 1 | Janssen Research & Development, LLC | $25.00 | 03/10/2023 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants | No dispute reported | 06/30/2026 | 986108107 |
| Principal investigator 1 | Janssen Research & Development, LLC | $25.00 | 03/10/2023 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults | No dispute reported | 06/30/2026 | 986108121 |
| Principal investigator 1 | PFIZER INC. | $94,605.36 | 03/09/2023 | Non-covered Recipient Entity University Clinical Research DeLand LLC | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1046462545 |
| Principal investigator 1 | Novavax Inc | $6,078.00 | 03/08/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) | No dispute reported | 06/30/2026 | 1055260065 |
| Principal investigator 1 | Novavax Inc | $3,186.00 | 03/08/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 | No dispute reported | 06/30/2026 | 1055262065 |
| Principal investigator 1 | Janssen Research & Development, LLC | $200.00 | 03/06/2023 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults | No dispute reported | 06/30/2026 | 986108111 |
| Principal investigator 1 | Janssen Pharmaceuticals, Inc | $50.00 | 03/03/2023 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 986093505 |
| Principal investigator 1 | Novavax Inc | $900.00 | 03/02/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) | No dispute reported | 06/30/2026 | 1055265013 |
| Principal investigator 1 | ModernaTX, Inc. | $50.00 | 03/01/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041448421 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 03/01/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1006713025 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 03/01/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1006713043 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 03/01/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1006713057 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 03/01/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1006713073 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 03/01/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1006713091 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 03/01/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007200415 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 03/01/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007200425 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 03/01/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007200435 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 03/01/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007200447 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 03/01/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007200457 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 03/01/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007204175 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 03/01/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007204185 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 03/01/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007204202 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 03/01/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007204217 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 03/01/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007204231 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 03/01/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007204245 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 03/01/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007530775 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 03/01/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007530789 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 03/01/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007530803 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 03/01/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007530817 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 03/01/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007530827 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 03/01/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007530843 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 03/01/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007530857 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 03/01/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007673809 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 03/01/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007772833 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 03/01/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007772839 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 03/01/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007772845 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 03/01/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007772851 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 03/01/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007772859 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 03/01/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007822155 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 03/01/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007822161 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 03/01/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007822166 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 03/01/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007822171 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 03/01/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1008472987 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 03/01/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1008473001 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 03/01/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1008473013 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 03/01/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1008473027 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 03/01/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1008473043 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 03/01/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1008473059 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 03/01/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1008473073 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 03/01/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1008473089 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 03/01/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1008473101 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 03/01/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1009274207 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 03/01/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1009274225 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 03/01/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1009274241 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 03/01/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1009274259 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 03/01/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1009274277 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 03/01/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1009274293 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 03/01/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1009274309 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 03/01/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1009274331 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 03/01/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1009292475 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 03/01/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1009292491 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 03/01/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1009292507 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 03/01/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1009292523 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 03/01/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1009292541 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 03/01/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1009292557 |
| Principal investigator 1 | Novo Nordisk AS | $14.25 | 03/01/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1009292575 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $7,235.37 | 02/28/2023 | Non-covered Recipient Entity University Clinical Research-deland Llc Dba Accel Research Sites | Long-Term Study That Measures the Safety and Efficacy of BMS-986165 in Participants With Psoriasis | No dispute reported | 06/30/2026 | 1027490339 |
| Principal investigator 1 | Novavax Inc | $2,266.00 | 02/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) | No dispute reported | 06/30/2026 | 1055259097 |
| Principal investigator 1 | Novavax Inc | $3,582.00 | 02/28/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 | No dispute reported | 06/30/2026 | 1055259099 |
| Principal investigator 1 | Novo Nordisk AS | $2.60 | 02/24/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1006862321 |
| Principal investigator 1 | Novo Nordisk AS | $2.60 | 02/24/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1006862331 |
| Principal investigator 1 | Novo Nordisk AS | $2.60 | 02/24/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1006862340 |
| Principal investigator 1 | Novo Nordisk AS | $2.60 | 02/24/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1006862349 |
| Principal investigator 1 | Novo Nordisk AS | $26.86 | 02/24/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007543803 |
| Principal investigator 1 | Novo Nordisk AS | $26.86 | 02/24/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007543815 |
| Principal investigator 1 | Novo Nordisk AS | $26.86 | 02/24/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007543829 |
| Principal investigator 1 | Novo Nordisk AS | $9.00 | 02/24/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007543843 |
| Principal investigator 1 | Novo Nordisk AS | $20.52 | 02/24/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007543857 |
| Principal investigator 1 | Novo Nordisk AS | $20.52 | 02/24/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007543871 |
| Principal investigator 1 | Novo Nordisk AS | $20.52 | 02/24/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007543887 |
| Principal investigator 1 | Novo Nordisk AS | $20.52 | 02/24/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007543899 |
| Principal investigator 1 | Novo Nordisk AS | $20.52 | 02/24/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1007543913 |
| Principal investigator 1 | Novo Nordisk AS | $20.52 | 02/24/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1008093169 |
| Principal investigator 1 | Novo Nordisk AS | $36.00 | 02/24/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1008093183 |
| Principal investigator 1 | Novo Nordisk AS | $9.80 | 02/24/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1008093211 |
| Principal investigator 1 | Novo Nordisk AS | $60.00 | 02/24/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1008093225 |
| Principal investigator 1 | Novo Nordisk AS | $2.60 | 02/24/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1008093239 |
| Principal investigator 1 | Novo Nordisk AS | $2.60 | 02/24/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1008093255 |
| Principal investigator 1 | Novo Nordisk AS | $2.60 | 02/24/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1008093271 |
| Principal investigator 1 | Novo Nordisk AS | $2.60 | 02/24/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1008093286 |
| Principal investigator 1 | Novo Nordisk AS | $2.60 | 02/24/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1008093303 |
| Principal investigator 1 | Novo Nordisk AS | $5.70 | 02/24/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1008104429 |
| Principal investigator 1 | Novo Nordisk AS | $26.86 | 02/24/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1008104445 |
| Principal investigator 1 | Novo Nordisk AS | $26.86 | 02/24/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1008104459 |
| Principal investigator 1 | Novo Nordisk AS | $26.86 | 02/24/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1008104473 |
| Principal investigator 1 | Novo Nordisk AS | $26.86 | 02/24/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1008104491 |
| Principal investigator 1 | Janssen Pharmaceuticals, Inc | $16,463.00 | 02/23/2023 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 986093501 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,341.00 | 02/22/2023 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults | No dispute reported | 06/30/2026 | 986108119 |
| Principal investigator 1 | ModernaTX, Inc. | $104.62 | 02/22/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041450515 |
| Principal investigator 1 | Novavax Inc | $14,740.00 | 02/22/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) | No dispute reported | 06/30/2026 | 1055261067 |
| Principal investigator 1 | Novavax Inc | $10,443.00 | 02/22/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 | No dispute reported | 06/30/2026 | 1055262061 |
| Principal investigator 1 | ModernaTX, Inc. | $110.88 | 02/20/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041423729 |
| Principal investigator 1 | ModernaTX, Inc. | $66.00 | 02/20/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041423743 |
| Principal investigator 1 | ModernaTX, Inc. | $110.88 | 02/20/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041423773 |
| Principal investigator 1 | ModernaTX, Inc. | $110.88 | 02/20/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041423803 |
| Principal investigator 1 | ModernaTX, Inc. | $66.00 | 02/20/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041423817 |
| Principal investigator 1 | ModernaTX, Inc. | $66.00 | 02/20/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041423859 |
| Principal investigator 1 | ModernaTX, Inc. | $110.88 | 02/20/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041423873 |
| Principal investigator 1 | ModernaTX, Inc. | $110.88 | 02/20/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041423887 |
| Principal investigator 1 | ModernaTX, Inc. | $66.00 | 02/20/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041423901 |
| Principal investigator 1 | Janssen Research & Development, LLC | $19,672.00 | 02/17/2023 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 986108095 |
| Principal investigator 1 | ModernaTX, Inc. | $941.49 | 02/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041450423 |
| Principal investigator 1 | ModernaTX, Inc. | $8,473.39 | 02/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041450437 |
| Principal investigator 1 | ModernaTX, Inc. | $6,590.42 | 02/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041450453 |
| Principal investigator 1 | ModernaTX, Inc. | $9,414.88 | 02/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041450469 |
| Principal investigator 1 | ModernaTX, Inc. | $941.49 | 02/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041450483 |
| Principal investigator 1 | ModernaTX, Inc. | $2,057.13 | 02/17/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041450499 |
| Principal investigator 1 | ModernaTX, Inc. | $118.80 | 02/16/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041423717 |
| Principal investigator 1 | ModernaTX, Inc. | $118.80 | 02/16/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041423759 |
| Principal investigator 1 | ModernaTX, Inc. | $118.80 | 02/16/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041423789 |
| Principal investigator 1 | ModernaTX, Inc. | $118.80 | 02/16/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041423831 |
| Principal investigator 1 | ModernaTX, Inc. | $118.80 | 02/16/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041423845 |
| Principal investigator 1 | Novavax Inc | $50,875.00 | 02/16/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) | No dispute reported | 06/30/2026 | 1055259101 |
| Principal investigator 1 | Novavax Inc | $5,664.00 | 02/16/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 | No dispute reported | 06/30/2026 | 1055262063 |
| Principal investigator 1 | Janssen Pharmaceuticals, Inc | $2,916.00 | 02/15/2023 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 986093503 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,749.00 | 02/15/2023 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants | No dispute reported | 06/30/2026 | 986108097 |
| Principal investigator 1 | ModernaTX, Inc. | $941.49 | 02/15/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041450157 |
| Principal investigator 1 | ModernaTX, Inc. | $941.49 | 02/15/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041450173 |
| Principal investigator 1 | ModernaTX, Inc. | $941.49 | 02/15/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041450183 |
| Principal investigator 1 | ModernaTX, Inc. | $2,824.46 | 02/15/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041450197 |
| Principal investigator 1 | ModernaTX, Inc. | $941.49 | 02/15/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041450213 |
| Principal investigator 1 | ModernaTX, Inc. | $941.49 | 02/15/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041450229 |
| Principal investigator 1 | ModernaTX, Inc. | $2,824.46 | 02/15/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041450245 |
| Principal investigator 1 | ModernaTX, Inc. | $1,882.98 | 02/15/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041450259 |
| Principal investigator 1 | ModernaTX, Inc. | $2,824.46 | 02/15/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041450275 |
| Principal investigator 1 | ModernaTX, Inc. | $3,765.95 | 02/15/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041450295 |
| Principal investigator 1 | ModernaTX, Inc. | $1,882.98 | 02/15/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041450313 |
| Principal investigator 1 | ModernaTX, Inc. | $51,781.84 | 02/15/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041450327 |
| Principal investigator 1 | ModernaTX, Inc. | $32,952.08 | 02/15/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041450343 |
| Principal investigator 1 | ModernaTX, Inc. | $941.49 | 02/15/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041450359 |
| Principal investigator 1 | ModernaTX, Inc. | $18,829.76 | 02/15/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041450373 |
| Principal investigator 1 | ModernaTX, Inc. | $10,356.37 | 02/15/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041450391 |
| Principal investigator 1 | ModernaTX, Inc. | $13,180.83 | 02/15/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041450409 |
| Principal investigator 1 | Novo Nordisk AS | $29.50 | 02/14/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1008093197 |
| Principal investigator 1 | Astellas Pharma Inc | $1,700.00 | 02/13/2023 | Non-covered Recipient Entity ADVARRA INC DBA SCHULMAN ASSOCIATES | A Study About How ASP5354 Affects the Body in Healthy Adults and in Adults Whose Kidneys do Not Work Well | No dispute reported | 06/30/2026 | 1017348989 |
| Principal investigator 1 | Astellas Pharma Inc | $1,097.00 | 02/13/2023 | Non-covered Recipient Entity ADVARRA INC DBA SCHULMAN ASSOCIATES | A Study About How ASP5354 Affects the Body in Healthy Adults and in Adults Whose Kidneys do Not Work Well | No dispute reported | 06/30/2026 | 1017348993 |
| Principal investigator 1 | Astellas Pharma Inc | $273.00 | 02/13/2023 | Non-covered Recipient Entity ADVARRA INC DBA SCHULMAN ASSOCIATES | A Study About How ASP5354 Affects the Body in Healthy Adults and in Adults Whose Kidneys do Not Work Well | No dispute reported | 06/30/2026 | 1017349001 |
| Principal investigator 1 | ModernaTX, Inc. | $4,707.44 | 02/10/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041449932 |
| Principal investigator 1 | ModernaTX, Inc. | $302.80 | 02/10/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041449949 |
| Principal investigator 1 | ModernaTX, Inc. | $605.60 | 02/10/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041449965 |
| Principal investigator 1 | ModernaTX, Inc. | $1,882.98 | 02/10/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041449981 |
| Principal investigator 1 | ModernaTX, Inc. | $2,824.46 | 02/10/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041449997 |
| Principal investigator 1 | ModernaTX, Inc. | $3,652.83 | 02/10/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041450015 |
| Principal investigator 1 | ModernaTX, Inc. | $3,652.83 | 02/10/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041450031 |
| Principal investigator 1 | ModernaTX, Inc. | $1,818.85 | 02/10/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041450047 |
| Principal investigator 1 | ModernaTX, Inc. | $908.40 | 02/10/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041450063 |
| Principal investigator 1 | ModernaTX, Inc. | $1,514.00 | 02/10/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041450079 |
| Principal investigator 1 | ModernaTX, Inc. | $1,514.00 | 02/10/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041450097 |
| Principal investigator 1 | ModernaTX, Inc. | $9,414.88 | 02/10/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041450111 |
| Principal investigator 1 | ModernaTX, Inc. | $302.80 | 02/10/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041450127 |
| Principal investigator 1 | ModernaTX, Inc. | $2,422.40 | 02/10/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041450141 |
| Principal investigator 1 | PFIZER INC. | $96,355.50 | 02/10/2023 | Non-covered Recipient Entity University Clinical Research DeLand LLC | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1046448639 |
| Principal investigator 1 | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | $1,250.00 | 02/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1046565509 |
| Principal investigator 1 | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | $537.05 | 02/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1046565545 |
| Principal investigator 1 | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | $750.00 | 02/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1046565561 |
| Principal investigator 1 | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | $1,000.00 | 02/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1046565725 |
| Principal investigator 1 | Eli Lilly and Company | $26,550.00 | 02/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A MULTIPLE-DOSE DOSE-ESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF LY3372993 IN PARTICIPANTS WITH ALZHEIMER'S DISEASE | No dispute reported | 06/30/2026 | 1038149967 |
| Principal investigator 1 | Novavax Inc | $14,665.00 | 02/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) | No dispute reported | 06/30/2026 | 1055263997 |
| Principal investigator 1 | Novavax Inc | $5,841.00 | 02/09/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 | No dispute reported | 06/30/2026 | 1055263999 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $962.28 | 02/09/2023 | Non-covered Recipient Entity University Clinical Research Dela LLC | Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1035915103 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $3,000.00 | 02/09/2023 | Non-covered Recipient Entity University Clinical Research Dela LLC | Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1035915113 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $1,000.00 | 02/09/2023 | Non-covered Recipient Entity University Clinical Research Dela LLC | Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1035915123 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $500.00 | 02/09/2023 | Non-covered Recipient Entity University Clinical Research Dela LLC | Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1035915133 |
| Principal investigator 1 | Janssen Research & Development, LLC | $566.00 | 02/08/2023 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants | No dispute reported | 06/30/2026 | 986108099 |
| Principal investigator 1 | ModernaTX, Inc. | $1,818.85 | 02/08/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041449239 |
| Principal investigator 1 | ModernaTX, Inc. | $2,725.20 | 02/08/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041449251 |
| Principal investigator 1 | ModernaTX, Inc. | $4,844.80 | 02/08/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041449269 |
| Principal investigator 1 | ModernaTX, Inc. | $9,132.07 | 02/08/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041449281 |
| Principal investigator 1 | ModernaTX, Inc. | $4,239.20 | 02/08/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041449293 |
| Principal investigator 1 | ModernaTX, Inc. | $16,005.30 | 02/08/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041449309 |
| Principal investigator 1 | ModernaTX, Inc. | $6,964.40 | 02/08/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041449329 |
| Principal investigator 1 | ModernaTX, Inc. | $17,888.27 | 02/08/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041449343 |
| Principal investigator 1 | ModernaTX, Inc. | $909.43 | 02/08/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041449359 |
| Principal investigator 1 | ModernaTX, Inc. | $605.60 | 02/08/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041449375 |
| Principal investigator 1 | ModernaTX, Inc. | $302.80 | 02/08/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041449389 |
| Principal investigator 1 | ModernaTX, Inc. | $45,191.42 | 02/08/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041449407 |
| Principal investigator 1 | ModernaTX, Inc. | $302.80 | 02/08/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041449421 |
| Principal investigator 1 | ModernaTX, Inc. | $62,138.21 | 02/08/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041449437 |
| Principal investigator 1 | ModernaTX, Inc. | $42,366.96 | 02/08/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041449453 |
| Principal investigator 1 | ModernaTX, Inc. | $908.40 | 02/08/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041449469 |
| Principal investigator 1 | ModernaTX, Inc. | $941.49 | 02/08/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041449483 |
| Principal investigator 1 | ModernaTX, Inc. | $3,652.83 | 02/08/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041449501 |
| Principal investigator 1 | ModernaTX, Inc. | $302.80 | 02/08/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041449515 |
| Principal investigator 1 | ModernaTX, Inc. | $605.60 | 02/08/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041449531 |
| Principal investigator 1 | ModernaTX, Inc. | $909.43 | 02/08/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041449547 |
| Principal investigator 1 | ModernaTX, Inc. | $302.80 | 02/08/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041449565 |
| Principal investigator 1 | ModernaTX, Inc. | $302.80 | 02/08/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041449581 |
| Principal investigator 1 | ModernaTX, Inc. | $1,826.41 | 02/08/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041449597 |
| Principal investigator 1 | ModernaTX, Inc. | $302.80 | 02/08/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041449613 |
| Principal investigator 1 | ModernaTX, Inc. | $908.40 | 02/08/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041449629 |
| Principal investigator 1 | ModernaTX, Inc. | $2,728.28 | 02/08/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041449645 |
| Principal investigator 1 | ModernaTX, Inc. | $605.60 | 02/08/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041449664 |
| Principal investigator 1 | ModernaTX, Inc. | $302.80 | 02/08/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041449679 |
| Principal investigator 1 | ModernaTX, Inc. | $302.80 | 02/08/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041449693 |
| Principal investigator 1 | ModernaTX, Inc. | $5,479.24 | 02/08/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041449707 |
| Principal investigator 1 | ModernaTX, Inc. | $909.43 | 02/08/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041449725 |
| Principal investigator 1 | ModernaTX, Inc. | $302.80 | 02/08/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041449741 |
| Principal investigator 1 | ModernaTX, Inc. | $1,211.20 | 02/08/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041449755 |
| Principal investigator 1 | ModernaTX, Inc. | $4,707.44 | 02/08/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041449767 |
| Principal investigator 1 | ModernaTX, Inc. | $1,826.41 | 02/08/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041449783 |
| Principal investigator 1 | ModernaTX, Inc. | $302.80 | 02/08/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041449801 |
| Principal investigator 1 | ModernaTX, Inc. | $1,882.98 | 02/08/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041449819 |
| Principal investigator 1 | ModernaTX, Inc. | $1,211.20 | 02/08/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041449833 |
| Principal investigator 1 | ModernaTX, Inc. | $1,211.20 | 02/08/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041449853 |
| Principal investigator 1 | ModernaTX, Inc. | $1,882.98 | 02/08/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041449867 |
| Principal investigator 1 | ModernaTX, Inc. | $9,132.07 | 02/08/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041449885 |
| Principal investigator 1 | ModernaTX, Inc. | $5,479.24 | 02/08/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041449903 |
| Principal investigator 1 | ModernaTX, Inc. | $9,414.88 | 02/08/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041449917 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041420081 |
| Principal investigator 1 | ModernaTX, Inc. | $1,452.13 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041420095 |
| Principal investigator 1 | ModernaTX, Inc. | $2,201.40 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041420109 |
| Principal investigator 1 | ModernaTX, Inc. | $1,925.52 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041420123 |
| Principal investigator 1 | ModernaTX, Inc. | $1,285.35 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041420139 |
| Principal investigator 1 | ModernaTX, Inc. | $1,925.52 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041420151 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041420167 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041420179 |
| Principal investigator 1 | ModernaTX, Inc. | $52.80 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041420191 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041420204 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041420217 |
| Principal investigator 1 | ModernaTX, Inc. | $52.80 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041420235 |
| Principal investigator 1 | ModernaTX, Inc. | $1,452.13 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041420249 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041420263 |
| Principal investigator 1 | ModernaTX, Inc. | $2,201.40 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041420277 |
| Principal investigator 1 | ModernaTX, Inc. | $1,285.35 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041420291 |
| Principal investigator 1 | ModernaTX, Inc. | $2,201.40 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041420305 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041420321 |
| Principal investigator 1 | ModernaTX, Inc. | $1,285.35 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041420335 |
| Principal investigator 1 | ModernaTX, Inc. | $1,925.52 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041420349 |
| Principal investigator 1 | ModernaTX, Inc. | $2,201.40 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041420363 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041420377 |
| Principal investigator 1 | ModernaTX, Inc. | $2,201.40 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041420391 |
| Principal investigator 1 | ModernaTX, Inc. | $1,285.35 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041420405 |
| Principal investigator 1 | ModernaTX, Inc. | $1,452.13 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041420417 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041420431 |
| Principal investigator 1 | ModernaTX, Inc. | $2,201.40 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041420445 |
| Principal investigator 1 | ModernaTX, Inc. | $1,285.35 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041420459 |
| Principal investigator 1 | ModernaTX, Inc. | $1,925.52 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041420473 |
| Principal investigator 1 | ModernaTX, Inc. | $1,452.13 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041420487 |
| Principal investigator 1 | ModernaTX, Inc. | $1,925.52 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041420503 |
| Principal investigator 1 | ModernaTX, Inc. | $1,285.35 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041420517 |
| Principal investigator 1 | ModernaTX, Inc. | $1,285.35 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041420531 |
| Principal investigator 1 | ModernaTX, Inc. | $2,201.40 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041420545 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041420563 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041420579 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041420599 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041420613 |
| Principal investigator 1 | ModernaTX, Inc. | $1,841.00 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041420627 |
| Principal investigator 1 | ModernaTX, Inc. | $2,201.40 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041420641 |
| Principal investigator 1 | ModernaTX, Inc. | $1,925.52 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041420653 |
| Principal investigator 1 | ModernaTX, Inc. | $1,925.52 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041420667 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041420683 |
| Principal investigator 1 | ModernaTX, Inc. | $1,452.13 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041420697 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041420711 |
| Principal investigator 1 | ModernaTX, Inc. | $1,925.52 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041420727 |
| Principal investigator 1 | ModernaTX, Inc. | $1,452.13 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041420741 |
| Principal investigator 1 | ModernaTX, Inc. | $2,201.40 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041420753 |
| Principal investigator 1 | ModernaTX, Inc. | $1,452.13 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041420769 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041420783 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041420797 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041420809 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041420823 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041420837 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041420855 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041420867 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041420883 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041420895 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041420911 |
| Principal investigator 1 | ModernaTX, Inc. | $52.80 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041420927 |
| Principal investigator 1 | ModernaTX, Inc. | $52.80 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041420941 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041420955 |
| Principal investigator 1 | ModernaTX, Inc. | $1,285.35 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041420969 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041420983 |
| Principal investigator 1 | ModernaTX, Inc. | $1,452.13 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041420997 |
| Principal investigator 1 | ModernaTX, Inc. | $1,925.52 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041421009 |
| Principal investigator 1 | ModernaTX, Inc. | $1,285.35 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041421023 |
| Principal investigator 1 | ModernaTX, Inc. | $1,925.52 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041421037 |
| Principal investigator 1 | ModernaTX, Inc. | $2,201.40 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041421051 |
| Principal investigator 1 | ModernaTX, Inc. | $1,925.52 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041421065 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041421079 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041421093 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041421107 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041421121 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041421139 |
| Principal investigator 1 | ModernaTX, Inc. | $63.36 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041421151 |
| Principal investigator 1 | ModernaTX, Inc. | $63.36 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041421165 |
| Principal investigator 1 | ModernaTX, Inc. | $1,452.13 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041421180 |
| Principal investigator 1 | ModernaTX, Inc. | $1,925.52 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041421195 |
| Principal investigator 1 | ModernaTX, Inc. | $1,925.52 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041421207 |
| Principal investigator 1 | ModernaTX, Inc. | $1,452.13 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041421223 |
| Principal investigator 1 | ModernaTX, Inc. | $1,452.13 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041421237 |
| Principal investigator 1 | ModernaTX, Inc. | $1,925.52 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041421251 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041421265 |
| Principal investigator 1 | ModernaTX, Inc. | $1,285.35 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041421279 |
| Principal investigator 1 | ModernaTX, Inc. | $1,452.13 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041421293 |
| Principal investigator 1 | ModernaTX, Inc. | $1,285.35 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041421307 |
| Principal investigator 1 | ModernaTX, Inc. | $2,201.40 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041421321 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041421335 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041421349 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041421365 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041421379 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041421393 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041421407 |
| Principal investigator 1 | ModernaTX, Inc. | $1,925.52 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041421421 |
| Principal investigator 1 | ModernaTX, Inc. | $1,925.52 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041421435 |
| Principal investigator 1 | ModernaTX, Inc. | $1,452.13 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041421451 |
| Principal investigator 1 | ModernaTX, Inc. | $2,201.40 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041421465 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041421479 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041421493 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041421507 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041421521 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041421537 |
| Principal investigator 1 | ModernaTX, Inc. | $52.80 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041421553 |
| Principal investigator 1 | ModernaTX, Inc. | $52.80 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041421567 |
| Principal investigator 1 | ModernaTX, Inc. | $52.80 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041421579 |
| Principal investigator 1 | ModernaTX, Inc. | $52.80 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041421593 |
| Principal investigator 1 | ModernaTX, Inc. | $52.80 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041421605 |
| Principal investigator 1 | ModernaTX, Inc. | $2,201.40 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041421621 |
| Principal investigator 1 | ModernaTX, Inc. | $1,925.52 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041421635 |
| Principal investigator 1 | ModernaTX, Inc. | $2,201.40 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041421649 |
| Principal investigator 1 | ModernaTX, Inc. | $2,201.40 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041421663 |
| Principal investigator 1 | ModernaTX, Inc. | $2,201.40 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041421679 |
| Principal investigator 1 | ModernaTX, Inc. | $2,201.40 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041421693 |
| Principal investigator 1 | ModernaTX, Inc. | $1,925.52 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041421707 |
| Principal investigator 1 | ModernaTX, Inc. | $1,925.52 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041421723 |
| Principal investigator 1 | ModernaTX, Inc. | $2,201.40 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041421737 |
| Principal investigator 1 | ModernaTX, Inc. | $1,452.13 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041421749 |
| Principal investigator 1 | ModernaTX, Inc. | $2,201.40 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041421763 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041421779 |
| Principal investigator 1 | ModernaTX, Inc. | $52.80 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041421795 |
| Principal investigator 1 | ModernaTX, Inc. | $63.36 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041421809 |
| Principal investigator 1 | ModernaTX, Inc. | $1,452.13 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041421825 |
| Principal investigator 1 | ModernaTX, Inc. | $1,452.13 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041421839 |
| Principal investigator 1 | ModernaTX, Inc. | $1,285.35 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041421855 |
| Principal investigator 1 | ModernaTX, Inc. | $2,201.40 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041421867 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041421883 |
| Principal investigator 1 | ModernaTX, Inc. | $2,201.40 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041421897 |
| Principal investigator 1 | ModernaTX, Inc. | $2,201.40 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041421911 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041421923 |
| Principal investigator 1 | ModernaTX, Inc. | $2,201.40 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041421939 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041421953 |
| Principal investigator 1 | ModernaTX, Inc. | $1,925.52 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041421971 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041421985 |
| Principal investigator 1 | ModernaTX, Inc. | $1,452.13 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041421997 |
| Principal investigator 1 | ModernaTX, Inc. | $1,925.52 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041422011 |
| Principal investigator 1 | ModernaTX, Inc. | $1,452.13 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041422025 |
| Principal investigator 1 | ModernaTX, Inc. | $1,925.52 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041422039 |
| Principal investigator 1 | ModernaTX, Inc. | $2,201.40 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041422053 |
| Principal investigator 1 | ModernaTX, Inc. | $2,201.40 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041422065 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041422077 |
| Principal investigator 1 | ModernaTX, Inc. | $1,925.52 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041422090 |
| Principal investigator 1 | ModernaTX, Inc. | $1,285.35 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041422103 |
| Principal investigator 1 | ModernaTX, Inc. | $2,201.40 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041422113 |
| Principal investigator 1 | ModernaTX, Inc. | $2,201.40 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041422125 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041422137 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041422150 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041422161 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041422173 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041422187 |
| Principal investigator 1 | ModernaTX, Inc. | $52.80 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041422201 |
| Principal investigator 1 | ModernaTX, Inc. | $52.80 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041422211 |
| Principal investigator 1 | ModernaTX, Inc. | $52.80 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041422223 |
| Principal investigator 1 | ModernaTX, Inc. | $52.80 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041422241 |
| Principal investigator 1 | ModernaTX, Inc. | $1,285.35 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041422255 |
| Principal investigator 1 | ModernaTX, Inc. | $1,452.13 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041422269 |
| Principal investigator 1 | ModernaTX, Inc. | $2,201.40 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041422283 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041422297 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041422311 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041422325 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041422339 |
| Principal investigator 1 | ModernaTX, Inc. | $52.80 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041422353 |
| Principal investigator 1 | ModernaTX, Inc. | $52.80 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041422367 |
| Principal investigator 1 | ModernaTX, Inc. | $63.36 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041422381 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041422397 |
| Principal investigator 1 | ModernaTX, Inc. | $1,452.13 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041422409 |
| Principal investigator 1 | ModernaTX, Inc. | $1,925.52 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041422423 |
| Principal investigator 1 | ModernaTX, Inc. | $1,285.35 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041422437 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041422453 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041422468 |
| Principal investigator 1 | ModernaTX, Inc. | $2,201.40 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041422483 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041422499 |
| Principal investigator 1 | ModernaTX, Inc. | $1,925.52 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041422515 |
| Principal investigator 1 | ModernaTX, Inc. | $1,452.13 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041422527 |
| Principal investigator 1 | ModernaTX, Inc. | $1,285.35 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041422541 |
| Principal investigator 1 | ModernaTX, Inc. | $1,285.35 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041422551 |
| Principal investigator 1 | ModernaTX, Inc. | $1,452.13 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041422565 |
| Principal investigator 1 | ModernaTX, Inc. | $1,285.35 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041422579 |
| Principal investigator 1 | ModernaTX, Inc. | $1,452.13 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041422595 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041422609 |
| Principal investigator 1 | ModernaTX, Inc. | $2,201.40 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041422623 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041422637 |
| Principal investigator 1 | ModernaTX, Inc. | $2,201.40 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041422649 |
| Principal investigator 1 | ModernaTX, Inc. | $2,201.40 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041422663 |
| Principal investigator 1 | ModernaTX, Inc. | $1,285.35 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041422677 |
| Principal investigator 1 | ModernaTX, Inc. | $2,201.40 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041422690 |
| Principal investigator 1 | ModernaTX, Inc. | $1,452.13 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041422705 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041422719 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041422735 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041422747 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041422761 |
| Principal investigator 1 | ModernaTX, Inc. | $1,285.35 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041422779 |
| Principal investigator 1 | ModernaTX, Inc. | $2,201.40 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041422793 |
| Principal investigator 1 | ModernaTX, Inc. | $1,925.52 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041422807 |
| Principal investigator 1 | ModernaTX, Inc. | $1,925.52 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041422821 |
| Principal investigator 1 | ModernaTX, Inc. | $1,925.52 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041422835 |
| Principal investigator 1 | ModernaTX, Inc. | $2,201.40 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041422849 |
| Principal investigator 1 | ModernaTX, Inc. | $1,452.13 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041422863 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041422877 |
| Principal investigator 1 | ModernaTX, Inc. | $1,285.35 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041422891 |
| Principal investigator 1 | ModernaTX, Inc. | $1,285.35 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041422905 |
| Principal investigator 1 | ModernaTX, Inc. | $2,201.40 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041422919 |
| Principal investigator 1 | ModernaTX, Inc. | $2,201.40 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041422933 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041422947 |
| Principal investigator 1 | ModernaTX, Inc. | $1,452.13 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041422963 |
| Principal investigator 1 | ModernaTX, Inc. | $1,452.13 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041422977 |
| Principal investigator 1 | ModernaTX, Inc. | $2,201.40 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041422991 |
| Principal investigator 1 | ModernaTX, Inc. | $1,925.52 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041423007 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041423019 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041423033 |
| Principal investigator 1 | ModernaTX, Inc. | $52.80 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041423047 |
| Principal investigator 1 | ModernaTX, Inc. | $52.80 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041423061 |
| Principal investigator 1 | ModernaTX, Inc. | $1,925.52 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041423075 |
| Principal investigator 1 | ModernaTX, Inc. | $1,452.13 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041423091 |
| Principal investigator 1 | ModernaTX, Inc. | $1,452.13 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041423105 |
| Principal investigator 1 | ModernaTX, Inc. | $1,452.13 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041423119 |
| Principal investigator 1 | ModernaTX, Inc. | $1,925.52 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041423133 |
| Principal investigator 1 | ModernaTX, Inc. | $1,452.13 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041423150 |
| Principal investigator 1 | ModernaTX, Inc. | $1,452.13 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041423163 |
| Principal investigator 1 | ModernaTX, Inc. | $2,201.40 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041423177 |
| Principal investigator 1 | ModernaTX, Inc. | $2,201.40 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041423193 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041423207 |
| Principal investigator 1 | ModernaTX, Inc. | $1,452.13 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041423221 |
| Principal investigator 1 | ModernaTX, Inc. | $1,925.52 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041423237 |
| Principal investigator 1 | ModernaTX, Inc. | $1,452.13 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041423251 |
| Principal investigator 1 | ModernaTX, Inc. | $1,285.35 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041423265 |
| Principal investigator 1 | ModernaTX, Inc. | $1,925.52 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041423281 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041423293 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041423305 |
| Principal investigator 1 | ModernaTX, Inc. | $52.80 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041423319 |
| Principal investigator 1 | ModernaTX, Inc. | $1,452.13 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041423335 |
| Principal investigator 1 | ModernaTX, Inc. | $2,201.40 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041423351 |
| Principal investigator 1 | ModernaTX, Inc. | $1,285.35 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041423365 |
| Principal investigator 1 | ModernaTX, Inc. | $2,201.40 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041423377 |
| Principal investigator 1 | ModernaTX, Inc. | $1,925.52 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041423393 |
| Principal investigator 1 | ModernaTX, Inc. | $1,285.35 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041423407 |
| Principal investigator 1 | ModernaTX, Inc. | $1,285.35 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041423421 |
| Principal investigator 1 | ModernaTX, Inc. | $1,285.35 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041423435 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041423449 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041423461 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041423475 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041423489 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041423501 |
| Principal investigator 1 | ModernaTX, Inc. | $52.80 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041423515 |
| Principal investigator 1 | ModernaTX, Inc. | $52.80 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041423529 |
| Principal investigator 1 | ModernaTX, Inc. | $52.80 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041423543 |
| Principal investigator 1 | ModernaTX, Inc. | $52.80 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041423559 |
| Principal investigator 1 | ModernaTX, Inc. | $1,925.52 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041423571 |
| Principal investigator 1 | ModernaTX, Inc. | $1,452.13 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041423585 |
| Principal investigator 1 | ModernaTX, Inc. | $1,925.52 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041423599 |
| Principal investigator 1 | ModernaTX, Inc. | $2,201.40 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041423613 |
| Principal investigator 1 | ModernaTX, Inc. | $1,925.52 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041423629 |
| Principal investigator 1 | ModernaTX, Inc. | $1,925.52 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041423643 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041423657 |
| Principal investigator 1 | ModernaTX, Inc. | $1,452.13 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041423669 |
| Principal investigator 1 | ModernaTX, Inc. | $2,201.40 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041423685 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041423701 |
| Principal investigator 1 | ModernaTX, Inc. | $1,285.35 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041423915 |
| Principal investigator 1 | ModernaTX, Inc. | $1,285.35 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041423927 |
| Principal investigator 1 | ModernaTX, Inc. | $2,201.40 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041423941 |
| Principal investigator 1 | ModernaTX, Inc. | $1,285.35 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041423957 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041423971 |
| Principal investigator 1 | ModernaTX, Inc. | $1,285.35 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041423985 |
| Principal investigator 1 | ModernaTX, Inc. | $1,452.13 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041423999 |
| Principal investigator 1 | ModernaTX, Inc. | $1,925.52 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041424013 |
| Principal investigator 1 | ModernaTX, Inc. | $1,285.35 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041424028 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041424043 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041424059 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041424072 |
| Principal investigator 1 | ModernaTX, Inc. | $52.80 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041424087 |
| Principal investigator 1 | ModernaTX, Inc. | $52.80 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041424101 |
| Principal investigator 1 | ModernaTX, Inc. | $52.80 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041424115 |
| Principal investigator 1 | ModernaTX, Inc. | $52.80 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041424129 |
| Principal investigator 1 | ModernaTX, Inc. | $52.80 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041424143 |
| Principal investigator 1 | ModernaTX, Inc. | $2,201.40 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041424157 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041424171 |
| Principal investigator 1 | ModernaTX, Inc. | $1,285.35 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041424185 |
| Principal investigator 1 | ModernaTX, Inc. | $1,452.13 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041424199 |
| Principal investigator 1 | ModernaTX, Inc. | $1,925.52 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041424213 |
| Principal investigator 1 | ModernaTX, Inc. | $1,285.35 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041424227 |
| Principal investigator 1 | ModernaTX, Inc. | $2,201.40 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041424241 |
| Principal investigator 1 | ModernaTX, Inc. | $1,452.13 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041424255 |
| Principal investigator 1 | ModernaTX, Inc. | $2,201.40 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041424269 |
| Principal investigator 1 | ModernaTX, Inc. | $1,452.13 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041424283 |
| Principal investigator 1 | ModernaTX, Inc. | $2,201.40 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041424297 |
| Principal investigator 1 | ModernaTX, Inc. | $1,925.52 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041424311 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041424327 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041424341 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041424355 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041424372 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041424387 |
| Principal investigator 1 | ModernaTX, Inc. | $52.80 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041424401 |
| Principal investigator 1 | ModernaTX, Inc. | $52.80 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041424415 |
| Principal investigator 1 | ModernaTX, Inc. | $52.80 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041424429 |
| Principal investigator 1 | ModernaTX, Inc. | $52.80 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041424447 |
| Principal investigator 1 | ModernaTX, Inc. | $52.80 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041424461 |
| Principal investigator 1 | ModernaTX, Inc. | $2,201.40 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041424475 |
| Principal investigator 1 | ModernaTX, Inc. | $1,452.13 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041424489 |
| Principal investigator 1 | ModernaTX, Inc. | $2,201.40 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041424503 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041424519 |
| Principal investigator 1 | ModernaTX, Inc. | $1,452.13 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041424533 |
| Principal investigator 1 | ModernaTX, Inc. | $1,285.35 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041424547 |
| Principal investigator 1 | ModernaTX, Inc. | $1,925.52 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041424559 |
| Principal investigator 1 | ModernaTX, Inc. | $1,925.52 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041424573 |
| Principal investigator 1 | ModernaTX, Inc. | $2,201.40 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041424588 |
| Principal investigator 1 | ModernaTX, Inc. | $1,452.13 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041424603 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041424617 |
| Principal investigator 1 | ModernaTX, Inc. | $1,452.13 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041424631 |
| Principal investigator 1 | ModernaTX, Inc. | $2,201.40 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041424645 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041424659 |
| Principal investigator 1 | ModernaTX, Inc. | $52.80 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041424673 |
| Principal investigator 1 | ModernaTX, Inc. | $52.80 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041424687 |
| Principal investigator 1 | ModernaTX, Inc. | $52.80 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041424701 |
| Principal investigator 1 | ModernaTX, Inc. | $52.80 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041424715 |
| Principal investigator 1 | ModernaTX, Inc. | $1,000.00 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041424729 |
| Principal investigator 1 | ModernaTX, Inc. | $1,285.35 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041424743 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.38 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041424757 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041424769 |
| Principal investigator 1 | ModernaTX, Inc. | $52.80 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041424783 |
| Principal investigator 1 | ModernaTX, Inc. | $52.80 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041424799 |
| Principal investigator 1 | ModernaTX, Inc. | $1,925.52 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041424813 |
| Principal investigator 1 | ModernaTX, Inc. | $1,925.52 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041424827 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041424841 |
| Principal investigator 1 | ModernaTX, Inc. | $1,925.52 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041424855 |
| Principal investigator 1 | ModernaTX, Inc. | $1,452.13 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041424871 |
| Principal investigator 1 | ModernaTX, Inc. | $2,201.40 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041424885 |
| Principal investigator 1 | ModernaTX, Inc. | $2,201.40 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041424898 |
| Principal investigator 1 | ModernaTX, Inc. | $1,925.52 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041424911 |
| Principal investigator 1 | ModernaTX, Inc. | $1,925.52 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041424927 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041424942 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041424955 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041424971 |
| Principal investigator 1 | ModernaTX, Inc. | $2,201.40 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041424985 |
| Principal investigator 1 | ModernaTX, Inc. | $1,452.13 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041424999 |
| Principal investigator 1 | ModernaTX, Inc. | $539.22 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041425013 |
| Principal investigator 1 | ModernaTX, Inc. | $1,285.35 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041425029 |
| Principal investigator 1 | ModernaTX, Inc. | $1,285.35 | 02/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041425045 |
| Principal investigator 1 | PFIZER INC. | $54,980.50 | 02/03/2023 | Non-covered Recipient Entity University Clinical Research DeLand LLC | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1046437971 |
| Principal investigator 1 | UCB SA | $1,789.18 | 02/03/2023 | Non-covered Recipient Entity Accel Research Sites | A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND REPEAT-DOSE (PART B, PARTICIPANT-, INVESTIGATOR-, AND SPONSOR-BLIND) STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY (PART B ONLY) OF UCB1381 IN HEALTHY STUDY PARTICIPANTS (PART A) AND IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (PART B) | No dispute reported | 06/30/2026 | 1059100879 |
| Principal investigator 1 | Emergent BioSolutions Inc. | $1,475.48 | 02/02/2023 | Non-covered Recipient Entity University Clinical Research-Deland, LLC d/b/a Accel Research Sites | A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 | No dispute reported | 06/30/2026 | 1042864559 |
| Principal investigator 1 | Novavax Inc | $5,487.00 | 02/02/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 | No dispute reported | 06/30/2026 | 1055263085 |
| Principal investigator 1 | Janssen Research & Development, LLC | $500.00 | 02/01/2023 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults | No dispute reported | 06/30/2026 | 986108117 |
| Principal investigator 1 | ModernaTX, Inc. | $100.00 | 02/01/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041448301 |
| Principal investigator 1 | ModernaTX, Inc. | $100.00 | 02/01/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041448313 |
| Principal investigator 1 | ModernaTX, Inc. | $100.00 | 02/01/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041448327 |
| Principal investigator 1 | ModernaTX, Inc. | $100.00 | 02/01/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041448343 |
| Principal investigator 1 | ModernaTX, Inc. | $100.00 | 02/01/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041448355 |
| Principal investigator 1 | ModernaTX, Inc. | $100.00 | 02/01/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041448373 |
| Principal investigator 1 | ModernaTX, Inc. | $100.00 | 02/01/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041448389 |
| Principal investigator 1 | ModernaTX, Inc. | $100.00 | 02/01/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041448405 |
| Principal investigator 1 | ModernaTX, Inc. | $875.95 | 02/01/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041449225 |
| Principal investigator 1 | Eli Lilly and Company | $1,860.58 | 01/31/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | RANDOMIZED PLACEBO CONTROLLED PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN | No dispute reported | 06/30/2026 | 1038150659 |
| Principal investigator 1 | Janssen Research & Development, LLC | $118.00 | 01/31/2023 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 986108093 |
| Principal investigator 1 | Novo Nordisk AS | $8,000.00 | 01/31/2023 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1008104401 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $750.00 | 01/31/2023 | Non-covered Recipient Entity University Clinical Research Dela LLC | Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1035915187 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $1,250.00 | 01/31/2023 | Non-covered Recipient Entity University Clinical Research Dela LLC | Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1035915197 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $1,000.00 | 01/31/2023 | Non-covered Recipient Entity University Clinical Research Dela LLC | Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1035915209 |
| Principal investigator 1 | Janssen Research & Development, LLC | $513.50 | 01/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Randomized, Double-blind, Placebo-controlled Phase 1/2a Study for Safety and Immunogenicity Evaluations of various RSV.preF-based Vaccine Formulations in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 986140185 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 01/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041418043 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 01/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041418057 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 01/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041418071 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 01/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041418085 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 01/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041418099 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 01/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041418113 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 01/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041418127 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 01/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041418141 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 01/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041418155 |
| Principal investigator 1 | ModernaTX, Inc. | $198.00 | 01/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041418169 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 01/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041418183 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 01/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041418197 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 01/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041418211 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 01/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041418225 |
| Principal investigator 1 | ModernaTX, Inc. | $1,500.00 | 01/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041418239 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 01/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041418253 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 01/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041418267 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 01/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041418281 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 01/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041418295 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 01/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041418309 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 01/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041418323 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 01/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041418339 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 01/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041418355 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 01/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041418369 |
| Principal investigator 1 | ModernaTX, Inc. | $198.00 | 01/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041418385 |
| Principal investigator 1 | ModernaTX, Inc. | $100.00 | 01/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041418399 |
| Principal investigator 1 | ModernaTX, Inc. | $100.00 | 01/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041418411 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 01/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041418427 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 01/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041418441 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 01/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041418455 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 01/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041418469 |
| Principal investigator 1 | ModernaTX, Inc. | $100.00 | 01/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041418483 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 01/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041418497 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 01/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041418511 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 01/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041418525 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 01/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041418542 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 01/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041418557 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 01/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041418569 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 01/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041418583 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 01/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041418599 |
| Principal investigator 1 | ModernaTX, Inc. | $2,317.23 | 01/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041418613 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 01/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041418627 |
| Principal investigator 1 | ModernaTX, Inc. | $198.00 | 01/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041418643 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 01/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041418657 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 01/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041418671 |
| Principal investigator 1 | ModernaTX, Inc. | $2,317.23 | 01/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041419471 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 01/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041419485 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 01/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041419499 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 01/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041419513 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 01/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041419527 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 01/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041419540 |
| Principal investigator 1 | ModernaTX, Inc. | $500.00 | 01/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041419555 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 01/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041419569 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 01/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041419581 |
| Principal investigator 1 | ModernaTX, Inc. | $198.00 | 01/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041419595 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 01/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041419607 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 01/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041419623 |
| Principal investigator 1 | ModernaTX, Inc. | $100.00 | 01/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041419637 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 01/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041419651 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 01/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041419665 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 01/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041419679 |
| Principal investigator 1 | ModernaTX, Inc. | $1,245.61 | 01/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041419695 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 01/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041419711 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 01/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041419727 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 01/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041419741 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 01/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041419755 |
| Principal investigator 1 | ModernaTX, Inc. | $100.00 | 01/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041419769 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 01/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041419783 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 01/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041419795 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 01/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041419811 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 01/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041419825 |
| Principal investigator 1 | ModernaTX, Inc. | $7,500.00 | 01/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041419839 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 01/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041419851 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 01/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041419865 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 01/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041419879 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 01/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041419893 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 01/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041419908 |
| Principal investigator 1 | ModernaTX, Inc. | $750.00 | 01/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041419921 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 01/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041419935 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 01/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041419953 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 01/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041419967 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 01/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041419981 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 01/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041419993 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 01/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041420015 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 01/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041420027 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 01/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041420041 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 01/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041420053 |
| Principal investigator 1 | ModernaTX, Inc. | $99.00 | 01/30/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 1, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Multi-component Vaccines mRNA-1045 (Influenza and RSV) or mRNA-1230 (Influenza, RSV, and SARS-CoV-2) Compared With mRNA-1010 (Influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) Vaccines in Healthy Adults 50-75 Years of Age | No dispute reported | 06/30/2026 | 1041420067 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,960.00 | 01/27/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Randomized, Double-blind Phase 3 Study to Assess the Immunogenicity and Safety of an Ad26.RSV.PreF-based Regimen at the End of Shelf-life in Adults Aged 60 to Less Than 65Years | No dispute reported | 06/30/2026 | 986140179 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,500.00 | 01/27/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Randomized, Double-blind Phase 3 Study to Assess the Immunogenicity and Safety of an Ad26.RSV.PreF-based Regimen at the End of Shelf-life in Adults Aged 60 to Less Than 65Years | No dispute reported | 06/30/2026 | 986140181 |
| Principal investigator 1 | ModernaTX, Inc. | $141.07 | 01/27/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041448135 |
| Principal investigator 1 | ModernaTX, Inc. | $26,780.75 | 01/27/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041448153 |
| Principal investigator 1 | ModernaTX, Inc. | $337.50 | 01/27/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041448169 |
| Principal investigator 1 | ModernaTX, Inc. | $26,865.00 | 01/27/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041448185 |
| Principal investigator 1 | ModernaTX, Inc. | $27,000.00 | 01/27/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041448203 |
| Principal investigator 1 | ModernaTX, Inc. | $35,884.50 | 01/27/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041448219 |
| Principal investigator 1 | ModernaTX, Inc. | $40,500.00 | 01/27/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041448233 |
| Principal investigator 1 | ModernaTX, Inc. | $58,155.00 | 01/27/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041448251 |
| Principal investigator 1 | ModernaTX, Inc. | $86,400.00 | 01/27/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041448265 |
| Principal investigator 1 | ModernaTX, Inc. | $47,694.70 | 01/27/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041448283 |
| Principal investigator 1 | ModernaTX, Inc. | $40,297.50 | 01/27/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041449211 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $135,086.76 | 01/27/2023 | Non-covered Recipient Entity University Clinical Research Dela LLC | Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1035915255 |
| Principal investigator 1 | Eli Lilly and Company | $1,692.68 | 01/26/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A MULTIPLE-DOSE DOSE-ESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF LY3372993 IN PARTICIPANTS WITH ALZHEIMER'S DISEASE | No dispute reported | 06/30/2026 | 1038152017 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $7,500.00 | 01/26/2023 | Non-covered Recipient Entity University Clinical Research Dela LLC | Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1035915083 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $3,500.00 | 01/26/2023 | Non-covered Recipient Entity University Clinical Research Dela LLC | Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1035915093 |
| Principal investigator 1 | Janssen Pharmaceuticals, Inc | $41,741.00 | 01/25/2023 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 986093507 |
| Principal investigator 1 | Janssen Research & Development, LLC | $139.00 | 01/25/2023 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults | No dispute reported | 06/30/2026 | 986108113 |
| Principal investigator 1 | ModernaTX, Inc. | $13,122.00 | 01/25/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041448119 |
| Principal investigator 1 | Novavax Inc | $7,135.00 | 01/25/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 | No dispute reported | 06/30/2026 | 1055260063 |
| Principal investigator 1 | Averitas Pharma Inc. | $256.00 | 01/20/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN | No dispute reported | 06/30/2026 | 1058764383 |
| Principal investigator 1 | Janssen Pharmaceuticals, Inc | $322.00 | 01/20/2023 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 986093509 |
| Principal investigator 1 | Novavax Inc | $14,520.00 | 01/20/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 | No dispute reported | 06/30/2026 | 1055263087 |
| Principal investigator 1 | Janssen Research & Development, LLC | $11,062.50 | 01/19/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Randomized, Double-blind, Placebo-controlled Phase 1/2a Study for Safety and Immunogenicity Evaluations of various RSV.preF-based Vaccine Formulations in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 986140187 |
| Principal investigator 1 | PFIZER INC. | $8,000.00 | 01/19/2023 | Non-covered Recipient Entity University Clinical Research DeLand LLC | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1046537687 |
| Principal investigator 1 | Janssen Research & Development, LLC | $358.00 | 01/18/2023 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants | No dispute reported | 06/30/2026 | 986108101 |
| Principal investigator 1 | ModernaTX, Inc. | $12,245.71 | 01/18/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041448075 |
| Principal investigator 1 | ModernaTX, Inc. | $1,309.77 | 01/18/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041448089 |
| Principal investigator 1 | ModernaTX, Inc. | $500.00 | 01/18/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041448105 |
| Principal investigator 1 | Eli Lilly and Company | $1,273.46 | 01/13/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A PHASE 4 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GALCANEZUMAB VERSUS RIMEGEPANT IN ADULT PARTICIPANTS WITH EPISODIC MIGRAINE | No dispute reported | 06/30/2026 | 1038140123 |
| Principal investigator 1 | Janssen Pharmaceuticals, Inc | $300.00 | 01/11/2023 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 986093511 |
| Principal investigator 1 | ModernaTX, Inc. | $104,215.95 | 01/11/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1041448059 |
| Principal investigator 1 | Novavax Inc | $5,221.00 | 01/10/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) | No dispute reported | 06/30/2026 | 1055260061 |
| Principal investigator 1 | Eli Lilly and Company | $44,207.25 | 01/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A PHASE 4 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GALCANEZUMAB VERSUS RIMEGEPANT IN ADULT PARTICIPANTS WITH EPISODIC MIGRAINE | No dispute reported | 06/30/2026 | 1038151681 |
| Principal investigator 1 | Novavax Inc | $31,518.00 | 01/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 | No dispute reported | 06/30/2026 | 1055263995 |
| Principal investigator 1 | Novavax Inc | $2,325.00 | 01/06/2023 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) | No dispute reported | 06/30/2026 | 1055266027 |
| Principal investigator 1 | Janssen Research & Development, LLC | $25.00 | 01/04/2023 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults | No dispute reported | 06/30/2026 | 986108115 |
| Principal investigator 1 | Eli Lilly and Company | $103.53 | 01/03/2023 | Non-covered Recipient Entity MERIDIEN RESEARCH | RANDOMIZED PLACEBO CONTROLLED PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN | No dispute reported | 06/30/2026 | 1038110877 |